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Susanne M. Gollin, PhD 
Oral squamous cell carcinoma (OSCC) has a poor prognosis due to multiple factors including 
local recurrence, distant metastasis and therapeutic resistance. Our laboratory has demonstrated 
that the ATR-CHEK1 pathway is a critical modulator of radioresistance in OSCC; we evaluated 
the effectiveness of targeted CHEK1 inhibition in OSCC cancer stem-like cells (CSLC). To this 
end, we analyzed CSLC properties and the effect of ionizing radiation (IR) and CHEK1 
inhibition on CSLCs isolated from OSCC (parental) cell lines with and without distal 11q loss. 
The CSLCs, propagated in enriched serum-free medium, demonstrated stem-cell like 
characteristics including asymmetrical and symmetrical cell division, self-renewal, re-
differentiation, colony forming capacity at extreme (limiting) dilutions, and radioresistance.  
CHEK1 inhibitors affected the functional CSLC properties, resulting in significant 
reduction in proliferation, survival, colony initiation, growth, migration. The most drastically 
affected CSLC property was extracellular matrix migration. As determined by dose-response 
curves, a drug level ≈100-fold higher than the dose that was effective on parental OSCC cell 
lines was required to inhibit CSLC migration. 
Overall, our results suggest that distal 11q loss may predict radioresistance in CSLC; 
however, the CSLC response to IR-CHEK1 inhibition is not distal 11q loss-driven. CHEK1 
inhibitors increase the radiosensitivity of oral CSLC as they do for OSCC cell lines. Thus, we 
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 v 
propose that CHEK1 inhibition may be a useful adjuvant therapy for advanced and/or metastatic 
OSCC. 
PUBLIC HEALTH SIGNIFICANCE: Our results increased the understanding of cancer stem-
like cells in oral cancers and establish these cells as a contributing factor to radioresistance that 
could be potentially reversed in as many as 25% of cancers by CHEK1 inhibitors.  
 
 
 vi 
TABLE OF CONTENTS 
ACKNOWLEDGMENT ......................................................................................................... XVI 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 OVERVIEW ......................................................................................................... 1 
1.2 EPIDEMIOLOGY OF ORAL SQUAMOUS CELL CARCINOMA ............. 2 
1.3 CHARACTERISTICS OF ORAL CANCER STEM-LIKE CELLS ............. 5 
1.3.1 CSLC Hypothesis ............................................................................................. 5 
1.3.2 Basic properties of CSLCs .............................................................................. 9 
1.3.3 Isolation and identification of CSLC in HNSCC ........................................ 11 
1.3.4 Spheroid enrichment as a model for studying CSLCs ............................... 18 
1.3.5 Role of CSLC in prognosis ............................................................................ 19 
1.3.6 Role of CSLC in radioresistance .................................................................. 22 
1.3.7 Targeted approaches against CSLC ............................................................ 23 
1.4 CHARACTERISTICS OF ORAL SQUAMOUS CELL CARCINOMA..... 27 
1.4.1 Genetic Heterogeneity ................................................................................... 27 
1.4.2 Chromosomal Instability and Segregation Defects .................................... 29 
1.4.3 11q13 amplification ....................................................................................... 30 
1.4.4 Distal 11q Loss and Therapeutic Resistance ............................................... 31 
1.5 THE DNA DAMAGE RESPONSE (DDR) ...................................................... 34 
 vii 
1.5.1 Overview of the DDR .................................................................................... 34 
1.5.2 DNA Damage Repair Machinery ................................................................. 38 
1.6 CHEK1 INHIBITION AS A TARGETED CANCER THERAPY ............... 40 
1.6.1 TARGETED CANCER THERAPY ............................................................ 40 
1.6.2 CHEK1 INHIBITION ................................................................................... 42 
2.0 MATERIALS AND METHODS .............................................................................. 44 
2.1 CELL CULTURE .............................................................................................. 44 
2.1.1 OSCC cell lines............................................................................................... 44 
2.1.2 Control cell line .............................................................................................. 45 
2.1.3 CSLC cell cultures ......................................................................................... 45 
2.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ............................. 45 
2.2.1 Assessment of ATM copy number alterations ............................................. 45 
2.2.2 Assessment of Chromosomal Instability in CSLC...................................... 47 
2.3 IMMUNOFISH .................................................................................................. 47 
2.4 SPHEROID ENRICHMENT ASSAYS ........................................................... 48 
2.5 SPHEROID SELF-RENEWAL ASSESSMENT ............................................ 49 
2.6 SPHEROID SURVIVAL ASSAY .................................................................... 49 
2.7 SPHEROID GROWTH ASSAY ...................................................................... 50 
2.8 SPHEROID MIGRATION ZONE ASSESSMENT ....................................... 50 
2.9 CLONOGENIC COLONY SURVIVAL ASSAY ........................................... 51 
2.10 IMMUNOFLUORESCENCE (IF) ................................................................... 52 
2.10.1 Adherent IF ................................................................................................... 52 
2.10.2 Suspension IF ................................................................................................ 53 
 viii 
2.11 IMMUNOFLUORESCENCE ASSESSMENT ............................................... 54 
2.12 IMMUNOFLUORESCENCE ASSESSMENT OF GAMMA-H2AX, KU70 
AND P-CHEK1 FOCI ........................................................................................................ 54 
2.13 FLOW CYTOMETRY FOR CELL SURFACE MARKER ASSESSMENT ..  
  ............................................................................................................................. 55 
2.14 DIFFERENTIATION ASSAY ......................................................................... 56 
2.15 CELL CLONING BY SERIAL DILUTION ................................................... 56 
2.16 EXTREME LIMITING DILUTION ASSESSMENT .................................... 57 
2.17 MITOTIC CELL COLLECTION AND ANALYSIS .................................... 57 
2.18 CHROMOSOMAL SEGREGATION DEFECTS ASSESSMENT .............. 58 
2.19 CELL VIABILITY ASSAY .............................................................................. 59 
2.19.1 Live/Dead Viability/Cytotoxicity Kit .......................................................... 59 
2.19.2 Cell viability Assay using Trypan Blue Exclusion ..................................... 59 
2.20 STATISTICAL METHODS ............................................................................. 60 
2.20.1 General statistical methods .......................................................................... 60 
2.20.2 Assessment of prognostic significance of CSLC markers in OSCC ........ 60 
3.0 RESULTS ................................................................................................................... 62 
3.1 CSLC MARKERS IN OSCC CELL LINES ................................................... 62 
3.1.1 CSLC markers in OSCC cell lines ............................................................... 62 
3.1.2 Prognostic significance of CSLC markers in OSCC cell lines ................... 70 
3.2 DIVISION PATTERNS OF CSLC IN OSCC CELL LINES ........................ 73 
3.2.1 Division patterns of CSLC in OSCC cell lines ............................................ 73 
3.2.2 Division patterns in response to IR and enriched spheroid medium ........ 80 
 ix 
3.2.3 Chromosomal Segregation Defects in CSLC in OSCC cell lines .............. 82 
3.3 IMMUNOFISH OF CSLC IN OSCC CELL LINES ..................................... 85 
3.4 CHROMOSOMAL INSTABILITY IN CSLC FROM HNSCC AND OSCC 
CELL LINES ...................................................................................................................... 87 
3.5 SPHEROID ENRICHMENT IN OSCC CELL LINES ................................. 90 
3.6 CSLC RADIORESISTANCE PATTERNS IN OSCC ................................... 98 
3.6.1 Role of distal 11q loss in CSLC radioresistance ......................................... 98 
3.6.2 Role of CSLC in radioresistance ................................................................ 108 
3.7 COMBINED IR AND CHEK1 INHIBITION OF CSLC IN OSCC ........... 113 
4.0 DISCUSSION ........................................................................................................... 119 
4.1 CSLC MARKERS IN OSCC CELL LINES ................................................. 119 
4.2 PROGNOSTIC SIGNIFICANCE OF CSLC IN OSCC CELL LINES ..... 122 
4.3 DIVISION PATTERNS OF CSLC IN OSCC CELL LINES ...................... 123 
4.4 DISTAL 11Q LOSS AND CHROMOSOMAL INSTABILITY IN OSCC 
CSLC  ........................................................................................................................... 130 
4.5 SPHEROID ENRICHMENT IN OSCC ........................................................ 131 
4.6 CSLC RADIORESISTANCE PATTERNS IN OSCC ................................. 133 
4.7 COMBINED IR AND ATR/CHEK1 PATHWAY INHIBITION OF CSLC 
IN OSCC ........................................................................................................................... 136 
4.8 CONCLUSION ................................................................................................ 138 
APPENDIX A: CHEKI SMALL MOLECULE INHIBITOR .............................................. 141 
APPENDIX B: LIST OF ANTIBODIES USED FOR IF ...................................................... 142 
APPENDIX C: LIST OF ANTIBODIES USED FOR FLOW CYTOMETRY .................. 143 
 x 
APPENDIX D: ABBREVIATIONS ........................................................................................ 144 
BIBLIOGRAPHY ..................................................................................................................... 147 
 xi 
 LIST OF TABLES 
Table 1. Stem cell markers used in the identification of CSLC in HNSCC .......................... 17 
Table 2. Prognostic significance of CSLC Markers in HNSCC ............................................. 21 
Table 3. DDR Inhibitors in Clinical Use, Clinical Trials or under Developmenta ................ 38 
Table 4. Major DNA Repair Pathways ..................................................................................... 39 
Table 5. Measures of Central Tendency of CSLC-Positive (+++) Cells in UPCI:SCC Cell 
lines* as assessed by IF ............................................................................................................... 63 
Table 6. Prognostic significance of CSLC marker in a group of 18 OSCC cell linesa .......... 71 
Table 7. Immuno-FISH results of UPCI:SCC cell lines*......................................................... 86 
Table 8. FISH analysis of ATM copy number status in UPCI:SCC125 and derived clones 89 
Table 9. Stem cell frequency assessment by ELDA in OSCC cell lines in response to IR* 100 
Table 10. Stem cell frequency in OSCC cell lines, assessed by ELDA in response to 
combined IR and SMI CHEK1* .............................................................................................. 115 
 xii 
LIST OF FIGURES 
Figure 1. Epidemiological assessment of oral cancer in the US based on SEER data ............ 4 
Figure 2. Division patterns of CSLCs and their significance .................................................... 7 
Figure 3. Cancer Stem Cell Hypothesis: Hierarchic Model ...................................................... 8 
Figure 4. The two models of the CSLC hypothesis: the ‘Hierarchic’ and ‘Stochastic’ models
......................................................................................................................................................... 8 
Figure 5. Factors affecting CSLC survival ............................................................................... 11 
Figure 6. Schematic representation of the roles of ATM and ATR in the DDR signaling 
cascade ......................................................................................................................................... 37 
Figure 7. Schematic representation of the DDR signaling cascade ........................................ 37 
Figure 8. IF staining of UPCI:SCC029B with CSLC surface markers ................................. 64 
Figure 9. Frequencies of positive cells as assessed by CSLC surface markers ..................... 64 
Figure 10. IF staining of UPCI:SCC029B with CSLC markers ............................................. 65 
Figure 11. Frequencies of positive cells as assessed by CSLC markers ................................. 65 
Figure 12. IF of the control cell line, OKF6 with CSLC markers .......................................... 66 
Figure 13. Frequencies of positive cells as assessed by CSLC markers in the control cell 
line, OKF6 .................................................................................................................................... 66 
Figure 14. Double IF staining of UPCI:SCC029B with CSLC markers ................................ 67 
Figure 15. Double IF staining of OSCC cell lines utilizing CSLC marker combinations .... 68 
 xiii 
Figure 16. Flow cytometric analysis of OSCC tumor cells isolated and cultured under 
identical conditions ..................................................................................................................... 69 
Figure 17. Kaplan-Meier survival analysis of CSLC (high) in 18 OSCC cell lines .............. 72 
Figure 18. SOX2 as a marker of CSLC division ...................................................................... 75 
Figure 19. Mitotic Pair analysis of a representative image from the cell line, UPCI:SCC131 
showing significant differences in cell size ................................................................................ 76 
Figure 20. Mitotic Pair analysis of representative images of the cell line UPCI:SCC131 in 
different stages of division .......................................................................................................... 77 
Figure 21. Double immunofluorescence staining of SOX2+ CSLC with markers of cell 
division α-tubulin and phospho-Histone H3 ............................................................................. 78 
Figure 22. Immunofluorescence staining of CSLC markers in OSCC cell lines during cell 
division ......................................................................................................................................... 79 
Figure 23. SOX2+ CSLC division in response to IR and enriched SC medium ................... 81 
Figure 24. Chromosomal segregation defects in CSLC (SOX2+) CSLC and non-CSLC 
(SOX2-) 36 hrs after 2.5 Gy IR in OSCC cell lines (UPCI:SCC040 and 131) ....................... 83 
Figure 25. Chromosomal segregation defects in CSLC (SOX2+) 36 hrs after 2.5 Gy IR .... 84 
Figure 26. Immuno-FISH results showing ATM copy number alterations in OSCC cell lines 
with and without distal 11q loss ................................................................................................. 86 
Figure 27. FISH analyses of CSLC isolated from HNSCC#13 and clone HNSCC#13 E8 ... 88 
Figure 28. FISH images of CSLC derived from UPCI:SCC125 and UPCI:SCC125 clones 
showing ATM copy number alterations .................................................................................... 89 
Figure 29. Phase contrast images of spheroids derived from UPCI:SCC cell lines .............. 92 
Figure 30. Primary and secondary spheroid formation in UPCI:SCC cell lines .................. 93 
 xiv 
Figure 31. Correlation analysis between CD133 positive (+++) cells and spheroid formation 
showing a strong correlation ...................................................................................................... 94 
Figure 32. Correlation analysis between CD44 positive (+++) cells and spheroid formation 
showing a weak correlation ........................................................................................................ 94 
Figure 33. IF staining of spheroids enriched from OSCC cell line UPCI:SCC029B showing 
positive cells in enriched spheroids and grape-like colonies ................................................... 95 
Figure 34. Stem cell frequency assessment by extreme limiting dilution analysis ................ 96 
Figure 35. Differentiation assay of OSCC CSLC ..................................................................... 97 
Figure 36. Spheroid survival assay in UPCI:SCC cell lines after treatment with IR ......... 101 
Figure 37. Spheroid survival Assay in UPCI:SCC cell lines ................................................. 102 
Figure 38. Clonogenic survival of UPCI:SCC cell lines after treatment with IR ............... 103 
Figure 39. Clonogenic survival assay in parental OSCC cell lines ....................................... 104 
Figure 40. Assessment of CSLC survival in cells with and without distal 11q loss grown on 
matrigel-coated plates ............................................................................................................... 105 
Figure 41. Spheroid growth assay in OSCC cell lines with distal 11q loss .......................... 106 
Figure 42. Spheroid growth assay in OSCC cell lines without distal 11q loss .................... 106 
Figure 43. Assessment of spheroid growth assay in OSCC cell lines ................................... 107 
Figure 44. Assessment of spheroid growth in OSCC cell lines with distal 11q loss and 
without distal 11q loss ............................................................................................................... 107 
Figure 45. Spheroid survival assay in OSCC cell lines after treatment with IR regimens 109 
Figure 46. Quantification of spheroid-based migration in response to IR .......................... 110 
Figure 47. DNA damage response in cancer stem-like cells enriched from UPCI:SCC cell 
lines in response to IR ............................................................................................................... 112 
 xv 
Figure 48. Spheroid survival in CSLC with and without distal 11q loss in response to 
combined IR and CHEK1 SMI (+/- SEM) .............................................................................. 114 
Figure 49. Cell viability in response to combined IR and CHEK1 SMI inhibitor .............. 116 
Figure 50. Quantification of spheroid migration in response to combined IR2.5 and 
CHEK1 small molecule inhibitor ............................................................................................ 117 
Figure 51. Spheroid migration zone assay for short-term therapeutic assessment ............ 136 
 xvi 
ACKNOWLEDGMENT 
I am extremely grateful to my advisor, Dr. Susanne M. Gollin for providing me the opportunity 
to work in her laboratory and for instilling in me the qualities of a good researcher and mentor. I 
would also like to thank all agencies that funded the project, including the Fulbright Foundation, 
the Egyptian Ministry for High Education and the Joan G. Gaines Cancer Research Fund at the 
University of Pittsburgh.  
I thank the members of my thesis committee, Drs. Zsolt Urban, Eric Lagasse and Rahul 
Parikh for their guidance and taking time to answer my questions in spite of their busy schedules. 
I greatly appreciate the guidance and precious advice from Dr. Eric Lagasse that included 
experimental design recommendation such as extreme limiting dilution and antibody selection, 
such as CD133/1, in addition to providing cancer stem cell cells isolated from primary tumors. I 
greatly appreciate the advice from Dr. Zsolt Urban concerning the double staining experiments 
and the cluster plotting/analysis of cancer stem-like cell division. Furthermore, I also would like 
to thank Dr. William Saunders for advice on the cell division experiments and for sharing some 
cell division antibodies. I would also like to thank Mr. Dale Lewis, who helped train me in 
experimental design, cell culture techniques and FISH; Mr Dale Lewis also did the CSLC CIN 
experiments. I would also like to thank the past and present members of the Gollin laboratory for 
making my experience extremely rewarding. I am grateful for the assistance of, Dr. Paolo Piazza 
for helping with the flow-cytometry experiments; Dr. Khaled Hemada, research fellow in Mayo 
 xvii 
Clinic, Rochester, MI for his statistical advice and for analyzing the survival data; Laura McLean 
for helping with the phase imaging capturing; Megan Bresky, MSc Student and Samuel Wilshire, 
undergraduate student who worked at some time points on the project, Imgenex corporation for 
providing cancer stem cell antibodies, Miltenyi Corporation for providing the new CD133/1 
viobright. 
I would finally like to dedicate this work to my wife Tammy Novotne, family and friends 
for supporting and believing in me. Lastly, I would especially like to dedicate the current work to 
my past mentors, the late Dr Soheir Abdel-latif, Professor of Microbiology, NCI, Cairo 
University; Dr Amira Khorshid, Professor of Hematology, NCI, Cairo University and Dr Tarek 
Mansour, Professor of Immunology and Vice Director of Children Cancer Hospital (57357).  
 
 
 1 
1.0  INTRODUCTION 
1.1 OVERVIEW 
Cancer is the second leading cause of death in the United States of America (USA) despite the 
major improvements in the management of this disease. Resistance to conventional therapy is a 
significant cause of recurrence and mortality in cancer patients. Cancer is a very complex 
disease, with different clinical presentations, molecular types, grades and staging all affecting 
treatment and overall survival (OS). Cancer has been shown to be driven by genetic defects that 
accumulate over time. One of the approaches that can be utilized to determine the most effective 
therapy for a particular cancer is genetic profiling to identify the best treatment for that cancer 
based on comparative diagnostic biomarkers. Studies have shown that cancer stem-like cells 
(CSLC) are playing an important role in the therapeutic resistance in many tumors. Our groups’ 
previous studies have shown that a novel biomarker, the loss of distal chromosome 11q is 
associated with decreased sensitivity to radiation therapy (radioresistance) and better response to 
combined IR and targeted CHEK1 inhibitors. Understanding the role of distal 11q loss in CSLC 
is a good first step towards understanding the association between biomarkers and therapeutic 
resistance. 
Molecular biomarkers aid in better selecting the right patients for certain therapeutic 
interventions, thereby leading to better management of the disease in this population. Molecular 
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biomarkers also open the door for the era of personalized therapy, in which the right drugs are 
given to the right patients. For example, a patient whose CSLCs have distal 11q loss may have a 
poor response to radiation therapy, but may have a favorable response to a combination of 
conventional radiation therapy and ATR-CHEK1 pathway small molecule inhibitor therapy. In 
conclusion, supplementing conventional therapy with a targeted inhibitor is expected to improve 
survival in patient subpopulations. Overall, the expected public health significance of molecular 
biomarkers and targeted approaches is expected to be substantial. 
1.2 EPIDEMIOLOGY OF ORAL SQUAMOUS CELL CARCINOMA 
Solid tumors in general and epithelial tumors in particular show clinical, pathological, 
phenotypical and biological heterogeneity, making the efficient treatment of such tumors 
difficult (Chen, et al. 2011b). Head and neck squamous cell carcinoma (HNSCC) is an epithelial 
tumor that is caused by multiple genetic alterations, chronic inflammation, and environmental 
factors (Gollin 2014) Major risk factors for HNSCC include tobacco smoking, alcohol 
consumption and HPV infection (Gollin 2014; Leemans, et al. 2011). 
HNSCC comprises approximately about 80% of the head and neck cancers seen in 
patients (Figure 1) (SEER 2015). HNSCC is recognized as the seventh most prevalent cancer 
worldwide (Gollin 2014). More than 60% of the head and neck cancers are classified as OSCC 
(Oral Squamous cell Carcinoma) (Siegel, et al. 2014; Siegel, et al. 2015). The estimated number 
of new cases of OSCC in the US in 2015 is more than 45,000 and the estimated deaths are more 
than 8,000 (Siegel, et al. 2015). OSCC is currently the eighth most common cancer in males in 
the USA, having a higher incidence than leukemia and liver tumors (Siegel, et al. 2015). OSCC 
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can affect any region of the oral cavity, which includes the lining of the cheeks, salivary glands, 
hard palate, retromolar trigone, floor of mouth, gums and tongue. Prognosis remains poor, with 
approximately 60% 5-year overall survival (OS) rate (Figure 1) (SEER 2015). This low survival 
rate is due to a number of factors such as local recurrence, distant metastasis and therapeutic 
resistance (Figure 1) (Prince, et al. 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
Figure 1. Epidemiological assessment of oral cancer in the US based on SEER data 
(SEER 2015) 
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A. Age-adjusted SEER incidence rates per 100,000; age-adjusted to the 2000 US standard 
population. Data extracted from SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, 
Iowa, New Mexico, Seattle, Utah, and Atlanta).  
B. 5-Year relative survival (%) by year of diagnosis. Data extracted from SEER 9 areas (San 
Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). 
C. Disease classification (%) 2005-2011. Data extracted from SEER 18 areas (San Francisco, 
Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey,  
Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, 
Kentucky, Louisiana, New Jersey and   Georgia excluding ATL/RG). Based on follow-up of 
patients into 2012. 
D. Percent distribution histology among histologically confirmed cases, 2008-2012. Data 
extracted from SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, 
Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, 
California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding 
ATL/RG). 
1.3 CHARACTERISTICS OF ORAL CANCER STEM-LIKE CELLS 
1.3.1 CSLC Hypothesis 
The CSLC hypothesis suggests that a subpopulation of the cells in the tumor possess the 
potential to self-renew and generate the entire heterogeneous tumor bulk in a unique pattern 
(Clarke, et al. 2006; Harper, et al. 2007; Prince, et al. 2007) (Figures 2-4). There are two models 
that explain how CSLC recapitulate the tumor. The first is the ‘stochastic model’ that entails that 
any cancer cell can acquire stemness properties through clonal evolution acquired through 
sequential mutations and copy number alterations and the second model is the ‘hierarchic 
model’, where the CSLC resides on the top of the cell hierarchy and divides symmetrically and 
asymmetrically in a similar pattern to other stem cells (SC), such as adult SCs (Figures 3, 4) 
(Odoux, et al. 2008). Many researchers believe that these two models are mutually exclusive, 
adding even more complexity to the understanding of the biology of these cells (Odoux, et al. 
2008). The hierarchic CSLC model is better understood than the stochastic model, and has 
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gained much support in the past few years. According to the hierarchic CSLC model, CSLC 
possess the unique ability to divide both asymmetrically to generate differentiated cells and 
symmetrically to self-renew (Figure 2) (Harper, et al. 2007; Lathia, et al. 2011).  The main aspect 
that remains unanswered concerning CSLCs is the exact origin of these cells. There are two 
possible explanations for how CSLCs originate, but none has gained compelling supportive 
evidence; the first being that CSLC form as a result of oncogenic mutations of normal tissue 
stem cells (Visvader 2011) and the second being that CSLC arise from non-CSLC that have 
acquired stemness properties (Blagosklonny 2007). 
CSLCs were shown first in hematopoietic cancers (Bonnet and Dick 1997) and later in 
solid tumors, such as gliomas (Bao, et al. 2006; Uchida, et al. 2000), lung cancer (Wang, et al. 
2013), hepatocellular carcinoma (Lingala, et al. 2010; Yin, et al. 2007), breast cancer (Al-Hajj, et 
al. 2003; Grimshaw, et al. 2008; Han and Crowe 2009; Ponti, et al. 2005), colon cancer (Odoux, 
et al. 2008; Ricci-Vitiani, et al. 2007), HNSCC (Prince, et al. 2007; Wilson, et al. 2013), prostate 
cancer (Li, et al. 2010; Sheng, et al. 2013; Su, et al. 2010), pancreatic cancer (Bunger, et al. 
2012), melanoma (Monzani, et al. 2007), gastric cancer (Tian, et al. 2012), esophageal cancer 
(Zhao, et al. 2012), and sarcoma (Fujii, et al. 2009). The amount of evidence that supports the 
hierarchic CSLC model has increased significantly especially in the past few years. Different 
terminologies have been used to describe these cells, such as cancer stem cells, cancer initiating 
cells, functional tumor stem cells, tumor initiating cells and cancer stem-like cells (Baumann, et 
al. 2008).  
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Figure 2. Division patterns of CSLCs and their significance 
CSLCs are unique cells that can divide both symmetrically and asymmetrically. On the left, the 
CSLC (blue) divides symmetrically to produce two CSLC (blue). On the right, the CSLC divide 
asymmetrically to produce a CSLC (blue) and a transient progenitor (grey); the transient 
progenitor can divide to produce two differentiated progeny cells (green). (Abbreviations: CSLC, 
cancer stem-like cell; Trans. Prog., Transient progenitor; Diff, Differentiated progeny cells). 
Symmetrical division is related to the CSLC trait of “self renewal” and Asymmetrical division is 
related to the CSLC trait of “Tumor growth initiation and heterogeneity”. 
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Figure 3. Cancer Stem Cell Hypothesis: Hierarchic Model 
Tumors are clonally heterogeneous (left). Each cell can produce more cells of the same clone 
(yellow, blue and green), only the CSLC (orange) has the ability to divide both symmetrically 
and asymmetrically to produce the entire heterogeneous tumor pattern (right). The model is 
referred to as the “Hierarchic Model.” 
 
Figure 4. The two models of the CSLC hypothesis: the ‘Hierarchic’ and ‘Stochastic’ models 
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1.3.2 Basic properties of CSLCs 
For a subpopulation to be defined as CSLC, it should show four main characteristics. Firstly, it 
should possess distinctive cell surface markers. Secondly, the homogenous CSLC population 
should be able to give rise to the phenotypically diverse original tumor. Thirdly, these CSLC 
should be able to generate tumors in immunodeficient mice from as few as 100-500 cells 
(Bhaijee, et al. 2012; Sheng, et al. 2013). Lastly, serial transplantation through multiple 
generations should be proven, thereby showing that these cells possess the ability to self-renew 
(Odoux, et al. 2008). The American Association for Cancer Research Workshop on Cancer Stem 
Cells considered successful quantitative orthotopic xerograft tumor transplantation as the most 
important characteristic proving CSLC (Clarke, et al. 2006). In addition, some researchers 
believe that selective resistance to radiation therapy and chemotherapy should also be shown. 
The CSLC – niche interaction regulates many of the properties of CSLC, and consists of both 
cellular (fibroblasts, endothelial cells) and non-cellular components, and is currently the most 
promising area of CSLC research. 
The unique survival capacity of the CSLC subpopulation has been attributed to multiple 
factors, such as self-renewal (Tian, et al. 2012), the enhanced ability to remove drugs (Liu, et al. 
2012), the ability to repair DNA damage (Bao, et al. 2006), overexpressed anti-apoptotic 
proteins, and the niche interaction (cellular-extracellular interaction) (Figure 5). The relative 
quiescence of CSLC is also an important factor that has been correlated to the therapeutic 
resistance of these cells (Tabor, et al. 2011), because CSLC can switch off their proliferative 
machinery during therapy, thereby leading to decreased chances of cellular damage. Thus, the 
CSLC model may explain the resistance patterns of many tumors to conventional therapies 
(Ponti, et al. 2005). The CSLC model may also explain tumor heterogeneity (Wang, et al. 2012). 
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Research has shown that as many as 30% of breast cancer patients show micrometastatic seeds in 
the bone marrow at the time of diagnosis, although fewer than half of these patients develop 
metastases (Al-Hajj, et al. 2003). The characteristics and associations of CSLC clearly show that 
these cells are clonal, either tumorigenic or non-tumorigenic; only when tumorigenic cells 
metastasize do tumors develop (Al-Hajj, et al. 2003). For any treatment regimen to be effective, 
it must be able to target this unique population of tumorigenic CSLC (Bao, et al. 2006; Damek-
Poprawa, et al. 2011). 
Studying the CSLC subpopulation within tumors was extremely difficult until the early 
2000s (Al-Hajj, et al. 2003; Locke, et al. 2005; Prince, et al. 2007). Important factors that 
impeded CSLC research include the difficulty of isolation, the inability to propagate CSLC in 
culture, and the inability to control mechanisms underlying key properties, such as asymmetrical 
division (Locke, et al. 2005). However, the last few years have shown a dramatic change due to 
the development of efficient isolation and in vitro propagation techniques, such as spheroid 
enrichment and flow sorting for cell surface markers (Fujii, et al. 2009; Lim, et al. 2011; Tian, et 
al. 2012). One of the approaches that have been used to isolate CSLC is flow sorting to identify 
the side population (SP) cells. SP isolation depends on the characteristic property of CSLC of 
Hoechst dye effluxion by multi-drug-like transporters (Han and Crowe 2009; Wan, et al. 2010). 
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(Adapted from Sayed, et al. 2011). 
 
Figure 5. Factors affecting CSLC survival 
 
The survival capacity of the CSLC subpopulation has been attributed to multiple factors, such as 
self-renewal, the enhanced ability to remove drugs, the ability to repair DNA damage, 
overexpressed anti-apoptotic proteins and the niche interaction (cellular-extracellular 
interaction)(Abbreviations: OSCC CSLC, Oral squamous cell carcinoma cancer stem-like cell; 
EMT, Epithelial mesenchymal transition). 
1.3.3 Isolation and identification of CSLC in HNSCC 
Many markers have been used to identify CSLC in epithelial tumors. No single surface 
marker or method can has been shown to be optimum in regards to identifying CSLC in HNSCC. 
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However, a number of markers have been replicated by many research groups using CD133, 
CD44 and ALDH1 enzymatic activity (Table 1). CD44 has been the most controversial of the 
markers used, CD133 has been shown to be less controversial and ALDH1 is the most promising 
and the least controversial of the markers used to date (Table 1). 
When using patient samples to isolate CSLC it is crucial to eliminate non-epithelial 
lineage cells, such as normal leukocytes, fibroblasts, endothelial, and mesothelial cells from the 
tumor specimens using cell surface markers such as CD2, CD3, CD10, CD16, CD18, CD31, 
CD64, and CD140b (Al-Hajj, et al. 2003; Prince, et al. 2007). The standardization of isolation 
techniques will certainly be a critical step that will enhance our ability to study this 
subpopulation. Some researchers recommend double-sorting when there is any suspicion of cell 
impurity and to confirm that the sorted cells represent CSLC (Prince, et al. 2007). Wilson et al. 
compared the most common isolation techniques, such as SP, ALDH1, and CD44 expression for 
HNSCC and concluded that CD44 was the most promising cell-sorting marker in HNSCC 
(Wilson, et al. 2013). 
CD133 is a 120-kDa unique pentaspan membrane glycoprotein marker of CSLC and their 
early progenitor cells (Damek-Poprawa, et al. 2011; Tirino, et al. 2008). The role of CD133 
seems unclear although some researchers believe that it plays a role in the organization of plasma 
membrane protrusions (Mizrak, et al. 2008). CD133 was one of the earliest markers used to 
isolate CSLC in hematological and neurological tumors (Fargeas, et al. 2003). It was also shown 
in hepatocellular carcinoma (Yin, et al. 2007), colon (Ricci-Vitiani, et al. 2007), prostate 
(Collins, et al. 2005), melanoma (Monzani, et al. 2007) and osteosarcoma (Tirino, et al. 2008). 
The pioneering work by Bao et al. on glioma tumor cells showed that CD133+ CSLC possess all 
the characteristics of CSLC (Bao, et al. 2006). The results confirmed that high expression of 
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CD133 is associated with higher risk of metastases in glioma (Bao, et al. 2006). These results 
encouraged some groups to use CD133 as a marker for identification and isolation of CSLC in 
HNSCC (Shrivastava, et al. 2015; Yu, et al. 2014). In laryngeal carcinoma, a subpopulation of 
around 5% of cells expressing CD133 was identified and analysis of this subpopulation 
confirmed that they possess CSLC properties (Wei, et al. 2014; Wei, et al. 2009). Chen et al. also 
successfully isolated CSLC from laryngeal cell line using CD133 and BMI1 (Chen, et al. 2011a).  
Zhang et al. found 2% - 3% CD133+ cells in a HNSCC cell lines and patient biopsies (Zhang, et 
al. 2010).  
The most well-studied cell surface marker that was used in isolation and characterization 
of CSLC from HNSCC is CD44 (Harper, et al. 2007; Joshua, et al. 2012; Locke, et al. 2005; 
Mack and Gires 2008; Prince, et al. 2007; Wilson, et al. 2013). CD44 is a cell surface 
glycoprotein receptor for hyaluronic acid, encoded by a single gene on chromosome 11p13 
(Sayed, et al. 2011). It is involved in aggregation, proliferation, adhesion, migration and 
metastasis of cancer cells (Rajarajan, et al. 2012; Trapasso and Allegra 2012). CD44 was first 
identified as a marker of CSLC in lung tumors utilizing immunohistochemistry (Penno, et al. 
1994). CD44 has been used to identify and isolate CSLCs from many tumor types, such as breast 
tumors (Al-Hajj, et al. 2003; Kim, et al. 2012), prostate (Guo, et al. 2012; Sheng, et al. 2013), 
pancreatic (Bunger, et al. 2012), and head and neck carcinomas (Prince, et al. 2007; Wilson, et 
al. 2013). In a huge bioinformatics study, increased CD44 expression in HNSCC was found 
relative to many other tumor tissue types and also normal epithelial tissue (Rajarajan, et al. 
2012). In HNSCC, different isoforms, CD44v3 and CD44v6 have also been seen to correlate 
with overall disease aggressiveness especially radioresistance and metastases (Trapasso and 
Allegra 2012). Prince et al. was the first to isolate a CSLC subpopulation from HNSCC 
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specimens using fluorescence-activated cell sorting (FACS) analysis using an antibody against 
CD44; further analysis showed that the CD44 positive cells highly co-expressed BMI1, another 
important marker of CSLC (Prince, et al. 2007). Harper et al. compared the expression of CD44, 
CD29, and CD133 as presumed markers of CSLCs in HNSCC tumors; and found that the CD44 
expression showed the highest correlation with tumor clonogenicity (Harper, et al. 2007). Other 
investigators such as Locke et al. (Locke, et al. 2005), Okamoto et al. (Okamoto, et al. 2009), 
Wilson et al. (Wilson, et al. 2013) and Su et al. (Su, et al. 2011) used CD44 to isolate and 
characterize CSLC from HNSCC cell lines. Okamoto et al. focused on the chemoresistance 
characteristics of this subpopulation, and found that ABCB1, ABCG2, CYP2C8, and TERT 
chemoresistance genes were upregulated in the CD44+ subpopulation (Okamoto, et al. 2009). 
While Harper et al. focused on the morphological aspects, cell cycle and apoptotic resistance 
patterns of CSLC (Harper, et al. 2007). Harper et al. also showed that the CD44 CSLC 
subpopulation showed enhanced chemoresistance and longer G2 phase of the cell cycle (Harper, 
et al. 2010). Other researchers have shown that CD44+ CSLC were more resistant to paclitaxel 
(Wilson, et al. 2013), cisplatin and docetaxel treatment (Su, et al. 2011). Some studies showed 
conflicting results regarding the significance of CD44 expression in head and neck tumors 
(Joshua, et al. 2012; Mack and Gires 2008). Some researchers argue that CD44s is highly 
expressed in HNSCC cells, making it a less reliable marker for CSLC identification (Mack and 
Gires 2008; Wilson, et al. 2013). Furthermore, Oh et al. showed functionally that CD44- cells 
also possess CSLC properties (Oh, et al. 2013). Overall, these conflicting reports suggest that it 
would be better to investigate other markers and to use more than one marker for isolation and 
characterization of CSLC. 
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ALDH1 enzymatic activity has been used as a marker of CSLC in many tumors, such as 
breast cancer (Morimoto, et al. 2009). ALDH1 plays a role in early differentiation of stem cells 
by oxidizing retinol to retinoic acid (Croker, et al. 2009). In HNSCC, ALDH1 was shown to be a 
successful marker for CSLC by Chen et al. (Chen, et al. 2009) and Clay et al. (Clay, et al. 2010) 
because it consistently fulfills all the criteria of being rare, recapitulate the tumor heterogeneous 
structure and shows serial dilution xenotransplantation. Krishnamurthy et al. have shown that the 
combination of CD44 and ALDH1 expression selects CSLC in HNSCC efficiently using an 
orthotopic xenograft model (Krishnamurthy, et al. 2010). Based on these promising results, many 
researchers now use both CD44+ and ALDH1+ to identify the CSLC population (Kiang, et al. 
2012). 
BMI1 is a polycomb group transcription repressor that mediates gene silencing by 
regulating chromatin structure (Liu, et al. 2012). In murine SC, in vivo and in vitro functional 
studies have demonstrated that Bmi-1 is essential for the self-renewal of neural SCs but not for 
their survival or differentiation. In HNSCC, BMI1 plays a crucial role in the self-renewal of 
CSLC and has been correlated with the tumor aggressiveness and carcinogenesis of HNSCC 
(Prince, et al. 2007). BMI1 has been found to be overexpressed in CSLC in HNSCC (Prince, et 
al. 2007; Tabor, et al. 2011; Zhang, et al. 2010). It has also been shown to be overexpressed in 
other tumors such as cancer breast (Wang, et al. 2012). The combined isolation and evaluation of 
CSLC by both BMI1 and another CSLC marker can therefore be helpful in the assessment of the 
CSLC subpopulation in HNSCC.  
SP cells have also been shown to a successful isolation approach for CSLC in HNSCC 
(Yu, et al. 2012). This technique was first described by Goodell et al. in bone marrow-derived 
cells using flow-cytometry (Goodell, et al. 1996). The unique drug efflux phenotype of SP cells 
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is determined by ATP-binding cassette G2 subfamily (ABCG2). This protein superfamily is 
responsible for the multiple drug-resistant traits shown by these cancers (Liu, et al. 2012). In 
HNSCC, Wan et al. were the first to isolate CSLC using the SP approach (Wan, et al. 2010). 
Overall, the controversy and inconsistency of cell surface markers used in the field of 
CSLC research has led many researchers to focus on the identification of other cell surface 
markers that might be more reliable and consistent. Recent promising markers include CD10 
(Fukusumi, et al. 2014), CD98 (Rietbergen, et al. 2014), CD163 (He, et al. 2014), CD166 (Yan, 
et al. 2013), CD200 (Jung, et al. 2015) and CD271 (Murillo-Sauca, et al. 2014).   
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Table 1. Stem cell markers used in the identification of CSLC in HNSCC 
Isolation strategy Stem Cell Marker % reported in samples  Region Reference
FACS/SPH CD133 ≈2 Oral (Zhang, et al. 2010)
FACS CD133 ≈3 Larynx (Wu, et al. 2011)
FACS SP/CD133 ≈0.3 Larynx (Wu, et al. 2011)
FACS CD133 ≈3 Larynx (Wei, et al. 2014; Wei, et al. 2009)
FACS CD133 <1 Head and neck (Harper, et al. 2007)
FACS/SPH CD133, BMI1 ≈3 Larynx (Chen, et al. 2011a)
FACS CD44 ≈6 Head and neck (Harper, et al. 2007)
FACS CD44 <10% Head and neck (Prince, et al. 2007)
FACS CD44 25 Head and neck (Joshua, et al. 2012)
FACS CD44 na Head and neck (Lim, et al. 2011)
FACS CD44 ≈4 Head and neck  (Harper, et al. 2010)
FACS CD44 90-100% Head and neck (Wilson, et al. 2012)
FACS CD44+/CD24− ≈37 Head and neck (Chen, et al. 2009)
FACS CD44+/CD24− /ALDH+ na Head and neck (Chen, et al. 2009)
FACS CD44/ALDH1 ≈2 Head and neck (Krishnamurthy, et al. 2010)
FACS CD44/ALDH1 na Oral (Chou, et al. 2015)
FACS CD44/ALDH na Head and neck (Chinn, et al. 2014)
FACS  ALDH1 ≈15 Head and neck (Wilson, et al. 2012)
FACS ALDH1 ≈8 Head and neck (Chen, et al. 2009)
FACS ALDH1 ≈4 Head and neck (Clay, et al. 2010)
FACS SP ≈17 Larynx (Wu, et al. 2011)
FACS SP 0.1-6.0 Oral (Yu, et al. 2014)
FACS SP ≈14 Larynx (Wan, et al. 2010)
FACS SP ≈1 Head and neck (Tabor, et al. 2011)
FACS SP ≈1 Head and neck (Wilson, et al. 2012)
FACS SP 0.1 Head and neck (Lim, et al. 2011)
FACS SP <1 Head and neck (Harper, et al. 2007)
SPH CD44 3 Head and neck (Okamoto, et al. 2009)
SPH SOX2 na Oral (Chou, et al. 2015)
SPH  β-catenin na Head and neck (Lee, et al. 2014)
SPH OCT4 na Head and neck (Lee, et al. 2014)
SPH OCT4 na Oral (Tsai, et al. 2014) 
SPH na na Head and neck (Shrivastava, et al. 2015)
SPH na na Oral (Yu, et al. 2014)
SPH na na Oral (Chen, et al. 2012)
SPH na na Head and neck (Lim, et al. 2011)
SPH na na Head and neck (Harper, et al. 2007)
SPH na na Head and neck (Lim, et al. 2012)  
Abbreviations: FACS - Flow cytometry cell sorting, SP – Side population flow sorting, SPH - 
spheroid enrichment, na - not available 
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1.3.4 Spheroid enrichment as a model for studying CSLCs 
Spheroid enrichment for CSLC is an efficient, economic and reliable approach for studying 
CSLC. It is used mainly to study the therapeutic response of CSLC. Different approaches have 
been standardized, making this approach reproducible by researchers (Foty 2011; Friedrich, et al. 
2009; Ho, et al. 2012; Vinci, et al. 2013). The three-dimensional (3D) culture of spheroids 
mimics how metastatic and growing cancer colonies would behave when treated with various 
chemotherapeutic agents system, adding another advantage to this approach. The 3D spheroid 
culture model can also be used to understand CSLC properties of invasion and migration, both 
being crucial properties associated with tumor initiation and subsequent relapse or recurrence 
(Vinci, et al. 2013).  
The main difficulties associated with using spheroids in CSLC research include the 
necessity of using advanced imaging equipment and that not all cell lines or primary tumors form 
spheroids in culture (Friedrich, et al. 2009; Woolard and Fine 2009). Furthermore, it is 
technically difficult to assess the extent of CSLC enrichment in the spheroids or isolate CSLC 
from the formed spheroids for further experimentation and analysis due to various factors such as 
high intra-spheroidal cell death and partial differentiation of progeny cells (Perego, et al. 2011; 
Woolard and Fine 2009). Using adherent systems with CSLC enriched media is rapidly gaining 
ground as an approach to efficiently grow and/or isolate CSLCs, overcoming much of the 
technical difficulties faced with non-adherent spheroids (Lim, et al. 2012; Woolard and Fine 
2009). The interaction between CSLC and the extracellular matrix components along with the 
high exposure of adherent CSLCs to the enriched media might be key mechanisms that result in 
the inhibition of CSLC differentiation and increased CSLC propagation in these adherent CSLC 
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models (Woolard and Fine 2009). Eventually, a combined spheroid and adherent system might 
be the best approach for researchers in this field. 
1.3.5 Role of CSLC in prognosis  
Studying the role of CSLCs in chemo- and radioresistance will lead to new diagnostic and 
prognostic tests that can aid in patient care. Researchers have shown that the CSLC markers, 
CD133 (Chiou, et al. 2008), CD44 (Chinn, et al. 2015; Joshua, et al. 2012; Kokko, et al. 2011; 
Lindquist, et al. 2012), SOX2 (Huang, et al. 2014; Li, et al. 2014), OCT4 (Tsai, et al. 2014) and 
ALDH1 (Zhou and Sun 2014) can predict tumor behavior, aggressiveness and determine the 
prognosis of patients (Table 2). However, as reviewed in Table 1, the value of CSLC in HNSCC 
did not yield consistent results; some researchers showed poor prognosis across all parameters, 
others showed poor prognosis in some parameters, interestingly few papers even showed 
favorable prognosis. Overall, these results show that more research is crucial before more major 
conclusions that could be drawn. 
Work by Chinn et al. (Chinn, et al. 2015), Joshua et al. (Joshua, et al. 2012), Kokko et al. 
(Kokko, et al. 2011) and Lindquist et al. (Lindquist, et al. 2012) all showed that CD44 can be 
used as a marker of prognosis. In a sample of 40 patients, Chinn et al. found that CD44 high 
positivity by flow-cytometry was associated with tumor size and stage, but not with metastatic 
spread or survival (Chinn, et al. 2015). Joshua et al. showed that a flow cytometric measurement 
of the frequency CD44 CSLCs in human tumors grown in mouse models can correlate with 
prognosis. A cut-off point of 15.2% discriminates between the good and bad prognostic groups 
(good prognostic group < 15.2% and the bad prognostic groups > 15.2%) (Joshua, et al. 2012). 
Using IHC in a sample of 135 patients, Kokko et al. found a strong correlation between CD44 
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overexpression and poor 5-year OS in patients with HNSCC (Kokko, et al. 2011). Interestingly, 
the group also found that heavy smoking and not heavy alcohol consumption to be significantly 
associated with CD44-high positivity in the tumors (Kokko, et al. 2011). Similarly, utilizing 
IHC, Lindquist et al. also found a strong correlation between CD44-high positivity and shorter 
OS in a group of 73 patients (Lindquist, et al. 2012). Both Kokko et al. and Lindquist et al. 
focused not only on the percentages of positive cells, but on the intensity of staining (Kokko, et 
al. 2011; Lindquist, et al. 2012).  These results show that CSLC cell surface markers, such as 
CD44 can be used to determine the prognosis of patients.     
SOX2 is another CSLC that has shown to be an independent prognostic significance in 
HNSCC (Table 2). In a recent study, Huang, et al. showed that CD44 and SOX2 are useful 
prognostic marker in a group of 66 oral tumors (Huang, et al. 2014). Another study confirmed 
this finding and showed that SOX2 expression in OSCC is specifically correlated with lymph 
node metastasis in 80 oral tumors (Michifuri, et al. 2012). Lee et al. and Chou et al. demonstrated 
that SOX2 overexpression correlates with decreased OS (Chou, et al. 2015; Lee, et al. 2014). A 
recent meta-analysis of SOX2 as a prognostic marker in HNSCC showed that SOX2 assessment 
by IHC was closely correlated with advanced TNM stage and decreased OS (Li, et al. 2014). 
A meta-analysis that assessed the value of ALDH1 as a HNSCC prognostic marker, 
showed that high ALDH1 CSLC was highly correlated with lymph node metastasis, decreased 
OS and decreased disease-free survival (DFS) (Zhou and Sun 2014). However, ALDH1 
expression was not significantly associated with tumor stage.  
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Table 2. Prognostic significance of CSLC Markers in HNSCC 
Stem Cell Marker  Region Reference Prognostic significance
CD44 Larynx (Esteban, et al. 2005) Favourable
CD44 Oral (Kosunen, et al. 2007) Variable
CD44 hypopharynx (Uwa, et al. 2011) Variable
CD44 Larynx (Yuce, et al. 2011) Variable
CD44 Larynx (de Jong, et al. 2010) Variable
CD44 Head and neck (Mack and Gires 2008) No
CD44 Head and neck (Chen et al., 2010) Variable 
CD44 Head and neck (Joshua, et al. 2012) Poor
CD44 Head and neck (Kokko, et al. 2011) Variable 
CD44 Oral (Lindquist, et al. 2012) Poor
CD44 Head and neck (Koukourakis et al.,2012) Poor
CD44 Head and neck (Chinn, et al. 2014) Variable
CD44 Oral (Huang, et al. 2014) Poor
CD133 Oral (Liu et al., 2013) Poor
CD44/CD44v Head and neck (Kawano, et al. 2004) Variable
CD44v6 Larynx (Staibano, et al. 2007) Poor
CD44v6 Larynx (Guo, et al. 2009) Poor
CD133 Larynx (Lu, et al. 2011) No
SOX2 Oral (Zullig et al., 2013) Poor
SOX2 Head and neck (Schrock et al., 2014) Poor
SOX2 Hypopharynx (Ge et al. 2010) No
SOX2 Salivary (Dai et al. 2014) Poor
SOX2 Oral (Du et al. 2013) Poor
SOX2 Larynx (Tang et al. 2011) Poor
SOX2 Larynx (Ye et al. 2013) No
SOX2 Hypopharynx and Larynx   (Gonzalez-Marquez, et al. 2014) No
SOX2 Oral (Michifuri et al., 2012) Variable
SOX2 Oral (Huang, et al. 2014) Poor
ALDH1 Head and neck (Chen et al., 2010) Poor
ALDH1 Head and neck (Koukourakis et al.,2012) Favourable 
ALDH1 Head and neck (Xu et al.,2013) Variable
ALDH1 Oral (Liu et al., 2013) Poor
ALDH1 Oral (Qian et al., 2013) Poor
ALDH1 Oral (Huang et al.,2014) Poor
ALDH1 Head and neck (Qian et al., 2014) Poor
ALDH1 Oral (Michifuri et al., 2012) Variable
 ALDH1 Oral (Huang, et al. 2014) Poor
OCT4 Hypopharynx (Ge et al. 2010) Poor
  OCT4 Oral (Huang, et al. 2014) Poor
  OCT4 Head and neck (Lee, et al. 2014) Poor
   β-catenin Head and neck (Lee, et al. 2014) Poor  
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1.3.6 Role of CSLC in radioresistance 
Radiotherapy is currently an important treatment modality for HNSCC, used either alone or in 
combination with chemotherapy for primary and recurrent cancers (Strojan, et al. 2015). 
Radiotherapy will remain a crucial component of therapy for HNSCC because these tumors tend 
to locally infiltrate important surrounding structure; in addition surgery is often difficult owing to 
the anatomical location. Research has shown that cell surface markers, CD133 and CD44 could 
be markers of radioresistance in tumors (Gallmeier, et al. 2011; Piao, et al. 2012; Xiao, et al. 
2012). Breast CSLC have been shown to survive various protocols of radiation treatment, and 
even show higher self-renewal potential on some protocols (Lagadec, et al. 2010). The SP cells 
from breast cancer cell lines were found to be more resistant to radiation than the non-SP cells 
(Han and Crowe 2009). Bao et al. showed that CD133-positive glioma CSLCs repaired 
radiation-induced DNA damage more efficiently than CD133-negative cells, and might be the 
source of tumor recurrence after radiation therapy (Bao, et al. 2006). CD133-positive non-small 
cell lung carcinoma (NSCLC) CSLCs are also radioresistant, due to defects in DNA repair which 
were manifested as decreased phosphorylation of various protein kinases, including ATM and 
Krüppel-associated protein 1 (KAP1) (Lundholm, et al. 2013). In prostate cancer, CD44-positive 
CSLCs were radioresistant when compared to parental cancer cells (Cho, et al. 2012), CD44 
knockdown was shown to enhance radiosensitivity (Xiao, et al. 2012). Taking a new approach in 
selecting CSLC, Ghisolfi et al. showed that irradiation enriched CSLCs in tumors, however this 
approach has not been replicated yet by others (Ghisolfi, et al. 2012). 
Few groups have begun working in the field of radioresistance in HNSCC CSLC; showing 
radioresistance using a number of different markers. Chen et al. found evidence that an ALDH1+ 
subpopulation exhibited increased radioresistance compared to ALDH- (Chen, et al. 2009). Wan 
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et al. also showed increased radioresistance of CSLC SP cells isolated from a laryngeal cell lines, 
AMC-HN-8 and Hep-2 (Wan, et al. 2010). On the other hand, Wilson et al. showed no 
significant differences in radiosensitivity between HNSCC cell lines using a number of different 
CSLC isolation techniques (Wilson, et al. 2012). Overall, radioresistance in HNSCC CSLCs is a 
promising field of research that we and others are exploring. 
1.3.7 Targeted approaches against CSLC 
Many groups are investigating the potential of certain targeted agents to selectively inhibit 
HNSCC CSLCs. Approaches include small molecule inhibitors such,  a WNT inhibitor (Warrier, 
et al. 2014); Cucurbitacin I, a STAT3 inhibitor (Chen, et al. 2010); compounds including 
Salinomycin and Quercetin (Basu, et al. 2011; Chang, et al. 2013); antibodies (Damek-Poprawa, 
et al. 2011); cell-based immunotherapy (Visus, et al. 2011); humanized monoclonal antibody 
anti-CD44v6 (bivatuzumab mertansine) (Tijink, et al. 2006); multifunctional experimental 
nanoparticles (Hermann, et al. 2010); a niche-based approach (Krishnamurthy, et al. 2010),  
histone deacetylase inhibitors (Giudice, et al. 2013); restoration of microRNA-200c (miR200c) 
(Lo, et al. 2011); and knockdown of critical stemness genes through small interfering RNA 
(siRNA)/short hairpin RNA (shRNA) against SNAI1 (Chen, et al. 2009), EZH2, OCT4 (Lo, et 
al. 2012), SMURF1 (Khammanivong, et al. 2014), and BMI1 (Chen, et al. 2011a). 
The results of applying specific anti-CSLC compounds are promising, but comparative 
analysis against parental cell lines is crucial to verify the sensitivity against CSLC (Basu, et al. 
2011; Chang, et al. 2013; Chen, et al. 2010). More research on the mechanisms by which 
Salinomycin and Quercetin affect CSLC is necessary before major conclusions can be drawn 
(Basu, et al. 2011; Chang, et al. 2013). Results using Cucurbitacin I look promising, but 
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replication by other groups and comparison with the current standard of care seem crucial (Chen, 
et al. 2010) 
In a phase 1 clinical trial, bivatuzumab, a humanized monoclonal antibody directed 
against CD44v6, covalently linked to the cytotoxic agent mertansine showed initial positive 
results, however serious severe skin reactions led to the discontinuation of any further clinical 
trials of this therapeutic modality (Tijink, et al. 2006). In an important study, Damek-Poprawa et 
al. showed that a targeted genotoxin against CD133-positive CSLCs in HNSCC is possible 
(Damek-Poprawa, et al. 2011). They used an anti-human CD133 monoclonal antibody (MAb) 
conjugated with a periodontal pathogen to target CD133-positive CSLCs in cell lines; the 
pathogen being characteristically sensitive against epithelioid-like cells (Damek-Poprawa, et al. 
2011).  Damek-Poprawa, et al. showed selective inhibition of the proliferative capacity against 
the CD133+ CSLC subpopulation (Damek-Poprawa, et al. 2011). Visus et al. successfully used 
an immunotherapeutic cell-based approach in which CD8+ T-cells specifically targeted the 
CSLC ALDH+ subpopulation within cell lines and fresh specimens (Visus, et al. 2011). They 
showed that ALDH+ CSLC are more tumorigenic when transplanted in immunodeficient mice at 
low dilution when compared to ALDH- (Visus, et al. 2011). They confirmed the inhibition of 
ALDH+ CSLC in vitro and in vivo using multiple approaches; animal model studies also yielded 
positive results in terms of increased mice survival (Visus, et al. 2011). In addition, Visus et al. 
used a novel intra-tumoral injection approach, thus proposing a clinical approach to the proposed 
therapeutic modality (Visus, et al. 2011).  Krishnamurthy et al. used a niche-based approach to 
decrease signaling between the CSLC and the perivascular niche (Krishnamurthy, et al. 2010). 
They ablated endothelial cells in the perivascular niche using a caspase-based artificial death 
switch and this lead to a decrease in the CD44+/ALDH+ cells subpopulation within the tumors. 
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These important results provide evidence for the potential use of anti-angiogenic drugs, such as 
bevacizumab in animal models to target CSLC.  
Chen et al. used a siRNA against SNAI1 (aliases - SNAIL), a key factor in maintaining 
CSLC properties through Epithelial Mesenchymal Transition (EMT) and reported that this 
approach can be used to overcome chemo- and radioresistance (Chen, et al. 2009). Chen et al. 
used shRNA to knockdown BMI1 and confirmed the critical role of BMI1 in laryngeal CSLC 
(Chen, et al. 2011a). BMI1 is an oncogene belonging to the Polycomb group (PcG) proteins 
family and has been shown to play a role in the proliferation of tumors and the self-renewal to 
CSLCs (Chen, et al. 2011a). Lo et al. used a non-viral gene delivery method to inhibit the CSLC 
subpopulation in an HNSCC cell line using a siRNA against EZH2 and OCT4 and showed weak 
inhibition of the ALDH1+/CD44+ CSLC subpopulation properties, such as EMT and 
radioresistance (Lo, et al. 2012). In addition, EZH2/OCT4 inhibition showed better results over 
radiation therapy alone in an animal model (Lo, et al. 2012). Some researchers consider this 
paper to have set the gold standard for the preliminary identification of a potential CSLC-
inhibitor because it used a non-viral vector, used an animal model and confirmed the 
effectiveness of the inhibition using multiple methods, such as cell survival, sphere formation 
and tumor invasion when compared to existing standard therapy IR (Kiang, et al. 2012). 
There are many other promising approaches that can be used to target the stemness self- 
renewal pathways of CSLC (Lee, et al. 2014; Takahashi-Yanaga and Kahn 2010). Warrier et al. 
used WNT antagonist in HNSCC and showed enhanced chemosensitivity to cisplatin and 
decreased spheroid formation which was reversed by the addition of WNT3A (Warrier, et al. 
2014). Silencing of SOX2 in vitro has been shown to decrease CSLC self-renewal, 
chemoresistance, invasion capacities and in vivo tumorigenicity in HNSCC (Lee, et al. 2014). 
 26 
SOX2 overexpression in HNSCC was found to lead to cyclin B1 and SNAI1 overexpression, as 
probable mechanism that might give these cells a survival advantage (Lee, et al. 2014). Targeting 
various stemness pathways may provide high therapeutic value; however, the side effects of such 
interventions, especially the effects on normal SC should be carefully investigated (Kaseb and 
Gollin 2015). For instance, NOTCH inhibitors have demonstrated marked toxicity affecting the 
gastrointestinal tract, muscle and immune systems in clinical and preclinical trials (Groth and 
Fortini 2012; Kaseb and Gollin 2015; Mourikis, et al. 2012).  Further, the important role of the 
NOTCH pathway in regulating squamous epithelial differentiation is consistent with reports of 
cutaneous disorders and malignancies as side effects of NOTCH inhibitors in an Alzheimer's 
disease clinical trial and in Notch1 knockout mice (Stransky, et al. 2011). To avoid possibly 
severe and life-threatening skin or muscle-related side effects, alternative therapeutic approaches 
should be examined, including intra-tumoral administration of NOTCH inhibitors in preclinical 
models, as suggested by Pickering et al. (Pickering, et al. 2013). Another approach may be to 
develop alternative small molecule inhibitors or antibodies to inhibit specific NOTCH receptors, 
their activating ligands, or other components of the NOTCH pathway in tumor cells (Fouillade, 
et al. 2012; Kaseb and Gollin 2015). For example, Wu et al. generated antibodies that can 
specifically target murine and human Notch receptors; short-term administration (2–3 weeks) 
showed fewer and less severe side effects compared to other Notch inhibitors (Wu, et al. 2010). 
Similarly, SOX2 targeting approaches have also been investigated. For instance, SOX2 
inhibition through a zinc finger-based artificial transcription factor approach has been successful 
in breast cancer cells (Stolzenburg, et al. 2012); Furthermore, a novel inhibitor of SOX2 DNA 
binding has been identified (Narasimhan, et al. 2011). Overall, these results and others clearly 
show that more research concerning the effects and side effects of inhibiting the stemness 
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pathway in normal cells and tumor cells is crucial before targeted therapeutic approaches against 
the stemness pathway are further implemented (Kaseb and Gollin 2015) 
1.4 CHARACTERISTICS OF ORAL SQUAMOUS CELL CARCINOMA 
1.4.1 Genetic Heterogeneity 
OSCC is a result of multiple genetic aberrations, which includes the inactivation of genes by 
deletion or mutations or the up-regulation of genes as a consequence of point mutation, 
amplification or other cytogenetic changes (Mitelman, et al. 2007).  Sequencing studies in OSCC 
and other solid tumors have shown that these tumors possess two types of genetic mutations. The 
first group is the ‘driver genes’ (usually around 5-10 per tumor) and mutations in these genes 
tend to initiate and drive the cancerous transformation of the cell. Driver gene mutations are 
important because they might determine the prognosis of the patient. The second group is called 
‘passenger gene' mutations and these occur from exposure to various environmental factors and 
defects caused by ‘driver' mutations (Lord and Ashworth 2012). In OSCC, four different critical 
driver pathways (mitogenic signaling, NOTCH, cell cycle, and TP53) were identified (Pickering, 
et al. 2013). Sequencing studies have confirmed that mutations in FAT1, CASP8, TP53, 
CDKN2A, PTEN, PIK3CA, HRAS, NOTCH1, IRF6, and TP63 are possible driver mutations in 
OSCC (Pickering, et al. 2013; Stransky, et al. 2011). 
The karyotypes of OSCC are usually complex, near-triploid, with various numerical and 
structural chromosome alterations abnormalities (Gollin 2014; Martin, et al. 2008). OSCC have 
been found to harbor more than 400 different chromosomal aberrations (Gollin 2014; Mitelman, 
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et al. 2014). The most common chromosomal abnormalities in OSCC are gains of 5p14-15, 
8q11-12, and 20q12-13, gains/amplifications of 3q26, 7p11, 8q24, and 11q13, and losses of 3p, 
4q35, 5q12, 8p23, 9p21-24, 11q14-23, 13q12-14, 18q23, and 21q22 (Gollin 2014). Using genetic 
expression profiles, researchers have classified OSCC into categories that aid in predicting 
prognosis in patients. Chung et al. proposed a classification for OSCC that categorized OSCC 
into four entities. The first group shows upregulation of transforming growth factor alpha and 
epidermal growth factor receptor (EGFR) pathway, and overall poor prognosis; The second 
group shows a strong mesenchymal cell signature, and poor prognosis possibly due to the higher 
risk of metastasis possibly due to EMT; the third group were biologically similar to normal 
squamous epithelial cells; and the last group showed an expression pattern unique to cigarette 
smoke exposure (Chung, et al. 2004). A more recent study validated and proposed a similar 
classification strategy, with types 1 through 4 being: basal, mesenchymal, atypical (often HPV+), 
and classical, respectively, based on the unique high genetic expression in each category (Walter, 
et al. 2013). 
CSLC regulatory genes, such as SOX2 and NOTCH1 have been found to be dysregulated 
in a proportion of OSCC patients. SOX2 gain has been shown to contribute to oncogenesis in 
OSCC; driving EMT an important characteristic of metastatic cells (Freier, et al. 2010; Lechner, 
et al. 2013). On the other hand, NOTCH gene mutations have been found in approximately 15% 
of head and neck tumors; and are usually complex, being associated with loss of-function, gain-
of-function, or both (Gaykalova, et al. 2014; Stransky, et al. 2011). Functional studies suggest 
that NOTCH1 may act as a tumor suppressor gene in HNSCC (Pickering, et al. 2013). 
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1.4.2 Chromosomal Instability and Segregation Defects 
Chromosomal instability (CIN) is a one of the important features of cancer cells. It refers to the 
gain or loss of entire or segments of chromosomes at a higher rate in a subpopulation of cells (Ha 
and Califano 2002). CIN is the result of multiple aberrations in multiple processes, including 
chromosomal segregation defects, cellular checkpoint abrogation, telomere instability, and DNA 
damage response (DDR) defects (Gollin 2005). The high prevalence of genetic alterations 
especially in solid tumors as they progress implies that CIN is both the cause and an effect of 
carcinogenic evolution (Lord and Ashworth 2012; Mitelman, et al. 2007). Although many of the 
processes/pathways involved in CIN are unrelated, they are interconnected at some points; 
adding complexity to CIN (Gollin 2005; Gollin 2014). CIN is indeed a double-edged weapon; 
defects in DDR can drive cancer cell resistance or evolution, on the other hand, CIN is the basis 
of many cancer therapeutic approaches such as IR and DNA crosslinking agents (Lord and 
Ashworth 2012). Chemotherapeutic agents, such as cisplatin induce covalent crosslinks between 
DNA bases that lead to DNA damage and apoptosis 
CIN can be in the form of structural or numerical alterations and may result in a change 
of the gene expression of the respective cells including oncogenes and tumor suppressor genes 
thereby driving carcinogenesis. CIN can also lead to a major dysfunction of normal cellular 
machinery including cell cycle regulation and DNA damage repair (Gollin 2005; Hanahan and 
Weinberg 2011; Shiloh 2003; Shiloh 2006). Overall, the net result is the evolution of cancer cells 
that will eventually lead to cancer growth and progression (Albertson 2006; Hanahan and 
Weinberg 2011). Structural CIN usually results from multiple breakage-fusion-bridge (BFB) 
cycles (Gollin 2005). Another important cause of CIN is chromosomal segregation defects 
(CSD). These defects in chromosomal segregation can lead to aneuploidy because of the 
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abnormal distribution of chromosomes to daughter cells (Gollin 2005; Reing, et al. 2004; 
Saunders, et al. 2000). The occurrence of CSD in OSCC was found to be an intrinsic and 
heritable property that occurs in primary tumors and cancer cell lines passages (Minhas, et al. 
2003; Reing, et al. 2004; Reshmi, et al. 2004; Saunders, et al. 2000). 
Defects in DNA double-strand breaks (DSB) repair are also an important cause of CIN 
because it results in genetic mutations, gene amplification, and chromosomal aberrations, which 
can drive carcinogenic evolution (Shiloh 2006; Shiloh 2014). However, the various 
interconnections between the DDR genes and CIN is not entirely clear (Gollin 2005). Cell cycle 
disturbances are also an important cause of CIN. In HNSCC, defects in the spindle assembly 
checkpoint have been shown to be a contributing factor to CIN (Minhas, et al. 2003). 
In colorectal cancer, CIN has been shown to be crucial in precancerous development as 
well as cancerous evolution of these tumors (Draviam, et al. 2004).  Siebers et al. showed that 
CIN assessed in pre-malignant oral lesions might aid in predicting malignant transformation in 
these lesions and in monitoring prognosis in malignant oral lesions (Siebers, et al. 2013). 
Understanding CIN in OSCC CSLC is one of the objectives of our current work. 
1.4.3 11q13 amplification 
Amplification of chromosomal band 11q13 is a common event in human cancer and it follows 
11q loss. Amplification increases the gene dosage and results in up-regulation of most of the 
distal genes (Huang, et al. 2006). 11q13 amplification was observed in ≈ 61% of OSCC patients 
(Gollin 2014; Huang, et al. 2006). 11q13 amplification in OSCC plays a role in early pre-
oncogenic transformation, enabling progression from moderate to severe dysplasia (Noutomi, et 
al. 2006; Salahshourifar, et al. 2014). Our group has shown previously that the 11q13 
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amplification in OSCC occurs by the BFB mechanism and that the loss of the distal part of 
chromosome 11q is an early step in this process (Reshmi, et al. 2007). The poor clinical 
correlation with 11q13 amplification was attributed specifically to amplification and 
overexpression of CCND1 and EMS1 (Schuuring 1995; Schuuring, et al. 1998). Other important 
genes amplified include, ORAOV1, ANO1 and FADD (Huang, et al. 2006; Wilkerson and Reis-
Filho 2013). CCND1 plays a crucial role in the regulation of the G1/S checkpoint and drives 
tumor growth in OSCC (Huang, et al. 2006). EMS1 encodes human cortactin, an actin binding 
protein possibly involved in the organization of the cellular cytoskeleton and cell adhesion 
structures (Wilkerson and Reis-Filho 2013) 
1.4.4 Distal 11q Loss and Therapeutic Resistance 
Research has shown that distal 11q deletion is the first step in the 11q13 amplification process in 
OSCC (Reshmi, et al. 2007). Loss of chromosomal material from 11q14-11q23 has been shown 
to occur in ∼50% of the HNSCC tumors examined (Gollin 2014; Martin, et al. 2008). Distal 11q 
loss has been shown to occur early in tumor intiation; in the transition of the tumor from 
carcinoma in situ (Califano, et al. 2000). The loss of distal 11q, where the DDR genes, MRE11A, 
ATM, and H2AFX are located, contributes to tumor development and progression (Parikh, et al. 
2007). Research has proven that haploinsufficiency of specific DDR genes (ATM, H2AFX, and 
MRE11A) is associated with CIN (Bassing, et al. 2003). Our group has shown that distal 11q loss 
occurs in a subset of tumors and can be used as a biomarker for prediction of radiosensitivity in 
HNSCC, lung and ovarian cancer cell lines and a companion diagnostic biomarker for 
combination therapy with ATR/CHEK1 pathway inhibitors (Parikh, et al. 2007; Sankunny, et al. 
2014). One of the important genes that plays a role in OSCC radioresistance is ATM (Sankunny, 
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et al. 2014). The ATM (ataxia-telangiectasia mutated) gene, located at 11q22.3 is a master 
regulator of DDR induced by agents such as IR. The sensor multiprotein complex MRE11A-
RAD50-NBN (MRN) complex activates ATM (Dai and Grant 2010). After ATM activation, 
ATM kinase activates a number of signaling pathways that leads to cell cycle arrest, apoptosis, 
and DNA repair (Jiang, et al. 2009). ATM activates these different pathways by phosphorylating 
its substrates, ABL1, TP53, NBN, BRCA1, and CHEK2 proteins (Shiloh 2014). ATM modulates 
DSB repair via nonhomologous end joining (NHEJ) in G1-phase, and via homologous 
recombination (HR) in S-phase and G2-phase (Branzei and Foiani 2008). Repair via HR is 
mediated through a vast collection of proteins that are phosphorylated downstream (Shiloh 
2014). Researchers have found it extremely difficult to define which of its downstream targets 
mediates the increased sensitivity to IR. The histone H2AX, is one of the critical substrates of 
ATM.  ATM activates H2AX specifically at the DSB regions, activating it through 
phosphorylation into γH2AX; γH2AX, then directs the recruitment of different DNA damage 
response proteins to the damaged site (Sankunny, et al. 2014; Stucki, et al. 2005).  
Ataxia Telangiectasia and Rad3-related (ATR) is a PI3K family protein involved mainly 
in the repair of stalled replication forks and maintenance of genetic integrity during S phase 
(Byun, et al. 2005). The ATR pathway regulates the DDR response primarily to ultraviolet 
radiation (UV) and agents that stall replication fork progression, such as aphidicolin and 
hydroxyurea (Gollin 2014). The ATR pathway is also interconnected with the ATM pathway. 
The interaction between ATR, ATR interacting protein (ATRIP) and replication protein A (RPA) 
plays an important role in the maintenance of chromosomal integrity (Sankunny, et al. 2014). 
The crucial role of ATR in the maintenance of genomic integrity was shown through loss of 
function experiments; where inhibition of ATR function led to CIN as a result of overexpression 
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of common fragile sites (Casper, et al. 2002). ATR phosphorylates a number of downstream 
proteins that includes BRCA1, CHEK1, MCM2, RAD17, RPA2, SMC1 and TP53, which 
activates cell cycle checkpoints as well as DNA repair and apoptosis pathways (Gollin 2014; 
Pruitt, et al. 2014). Overall, the various DDR pathways and networks are highly interconnected. 
The selective sensitivity of cancer cells to DNA-damaging IR suggests that interconnections 
between cell cycle checkpoint and survival pathways are altered in tumors. These pathway 
defects could be used to specifically enhance the killing of tumor cells.  
Our current study was designed to understand whether distal 11q loss plays a role in the 
response of OSCC CSLCs to radiation therapy. We used enriched tumorosphere assays which 
mimic the in vivo environment of cancers. This approach has also been shown to better predict 
radioresistance both on the short- and long-terms than standard clonogenic survival analysis 
(Bartucci, et al. 2012; Cho, et al. 2012). We used a CHEK1 inhibitor in conjunction with IR to 
study the effect of this combination on OSCC CSLCs. We hypothesized that the CHEK1 small 
molecule inhibitor (SMI) would reverse the radioresistance of our cell lines in a biomarker-
specific manner. Our group has shown previously that radioresistance in OSCC cell lines with 
distal 11q loss can be reversed by ATR-CHEK1 pathway inhibitors; whereas in OSCC cell lines 
without distal 11q loss, radiosensitivity is unaffected by ATR-CHEK1 pathway inhibition 
(Parikh, et al. 2013; Parikh, et al. 2007; Sankunny, et al. 2014). 
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1.5 THE DNA DAMAGE RESPONSE (DDR) 
1.5.1 Overview of the DDR 
The DNA damage response is a complex integrated system that maintains the genomic integrity 
of cells (Shiloh 2014). DNA damage can be a result of multiple causes that include UV, IR, 
hypoxia or environmental mutagens. DDR components interact with the cell cycle checkpoint 
and chromosome segregation machinery to repair DNA before the onset of mitosis (Warmerdam 
and Kanaar 2010).  
The cell cycle has three checkpoints that can be delayed to repair DNA damage before 
the onset of mitosis (Figure 5). These checkpoints are the G1-S, S phase, and the G2-M 
checkpoints. The G1-S checkpoint, the first of these checkpoints, is TP53-dependent and is 
regulated by ATM (Massague 2004). Unfortunately, the G1-S checkpoint is commonly 
dysregulated in OSCC and many other solid tumors (Michalides, et al. 2002). The S phase 
checkpoint is activated in response to DNA replication errors and DNA damage occurring during 
the S phase; ATR is one of the main regulators of this checkpoint (Sorensen, et al. 2003). Defects 
of the S phase checkpoint leads to premature mitosis, premature chromatin condensation (PCC), 
and mitotic apoptosis (Nghiem, et al. 2001). The aim of the G2-M checkpoint, the last 
checkpoint before the initiation of mitosis is to prevent cells with DNA damage or replication 
errors from initiating mitosis. This checkpoint is regulated by ATM/CHEK2 that phosphorylate 
CDC25A and prevent the activation of cyclin E/CDK2 (Figure 6) (Bucher and Britten 2008). In 
cells with defective G1-S and S phase checkpoints, targeting the G2M checkpoint with drugs that 
inhibit ATM/CHEK2, ATR/CHEK1 or CDC25 results in cell death by mitotic catastrophe and is 
a promising targeted anti-cancer therapeutic approach. 
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One type of DNA damage is the DSB, usually leads to a cascade of cellular DDR events 
that result in repair of the damage or cell death (Shiloh 2006; Shiloh 2014). DSB is induced by 
IR and oxygen free radicals (Shaheen, et al. 2011). Cells repair DSBs via either NHEJ or HR 
(Figure 6) (Abraham 2004). HR occurs after DNA replication, in the S and/or G2M cell-cycle 
phases, whereas NHEJ is occurs in G0/G1. HR is an accurate process because it uses the 
homologous template to repair the DSB; NHEJ on the other hand, is less accurate and utilizes 
end trimming (Shaheen, et al. 2011)  
DSB response can be divided into a three-tiered signaling cascade (Figure 7). ‘Sensor’ 
proteins detect and identify the damaged DNA and transmit signals to regulator ‘transducers’ 
that in turn transmit the signal switching on/off different ‘effector’ proteins. Important DNA 
damage sensor proteins include the MRE11A-RAD50-NBN (MRN) complex, TP53BP1 and 
MDC1 (Shiloh 2003; Shiloh 2006). One of the primary transducer proteins of the DSB cascade is 
the protein kinase ATM, which is a member of the PIKK family (Abraham 2004). The PIKK 
family consists of six members: ATM, ATR, PRKDC (protein kinase, DNA-activated, catalytic 
polypeptide), MTOR (mammalian target of rapamycin), SMG1 (suppressor of morphogenesis in 
genitalia-1) and TRRAP (transformation/transcription domain-associated protein) (Shiloh 2003). 
PRKDC, ATM, ATR and SMG1 play important roles in the DDR; ATM and PRKDC play a 
major role in the DSB cascade (Helt, et al. 2005). ATR, on the other hand, acts as a protein 
transducer in response to UV damage and stalled replication forks. Despite the fact that ATM 
and ATR have different functional roles in the DSB cascade, they are interconnected (Figure 6) 
(Shiloh 2006).  
Defects in the DDR have shown to be a cause of a variety of diseases including 
constitutional, inherited and somatic disorders. Defects in the DDR have been implicated directly 
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in familial predisposition to forms of cancer such as hereditary breast and ovarian cancer; the 
cause being loss of function mutations in HR genes, including BRCA1 and BRCA2 (Moynahan 
and Jasin 2010).  Congenital inherited disorders, such as Ataxia telangiectasia (AT), Li-Fraumeni 
and Fanconi anemia have been shown to harbor defects in the DDR pathways. The DDR has also 
been found to be markedly elevated in some precancerous lesions, as identified by a marker of 
DSBs, such as nuclear γH2AX foci (Bartkova, et al. 2006). 
Alterations in the DDR are crucial to the survival of CSLCs and tumor regrowth (Lord 
and Ashworth 2012). The pioneering work by Bao et al. showed that CSLCs have a more robust 
DDR and DNA repair activity when compared to non-CSLCs in gliomas (Bao, et al. 2006). They 
also showed that a DDR-targeted drug, such as a combined CHEK1/CHEK2 inhibitor, enhanced 
the killing of CSLCs induced by IR. Inhibition of these DDR proteins using targeted therapies is 
currently an important field of anti-cancer research (Table 3) (Hosoya and Miyagawa 2014). If 
such drugs can prevent cancer cells from repairing their damaged DNA, these cancer cells would 
lose their genetic integrity and die at an increased frequency in response to conventional 
therapies. Currently, more work is being done to investigate the appropriate dosing and 
scheduling of these inhibitors to decrease the side effects that have been observed in preclinical 
and clinical trials (Shaheen, et al. 2011). 
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Figure 6. Schematic representation of the roles of ATM and ATR in the DDR signaling 
cascade 
 
 
Figure 7. Schematic representation of the DDR signaling cascade 
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Table 3. DDR Inhibitors in Clinical Use, Clinical Trials or under Developmenta  
 
In Clinical Use 
Topoisomerase I inhibitor  
Topoisomerase II inhibitor  
In Clinical Trials 
CHEK1 inhibitor  
Combined CHEK1/CHEK2 inhibitor  
DNA-PK /mTOR inhibitor  
PARP inhibitor   
APE1 inhibitor  
MGMT inhibitor  
Under Development 
DNA protein kinase inhibitor  
MRE11 inhibitor  
ATM inhibitor  
ATR inhibitor  
CHEK2 inhibitor 
RAD51 inhibitor  
Telomerase inhibitor  
For current status and information of clinical trials, please refer to 
http://clinicaltrials.gov/, a service of the US National Institutes of Health.  
                    a Adapted from Hosoya and Miyagawa 2014 
 
1.5.2 DNA Damage Repair Machinery 
As discussed earlier, the causes of DNA damage are numerous and complex; to counteract this 
complexity, eukaryotic cells possess multiple complex DDR repair machinery comprised of 
multiple pathways (Table 4) (Lord and Ashworth 2012). Currently, there are more than 150 
different human proteins that play a role in DNA repair (Li, et al. 2012). Collectively, the five 
major DNA repair pathways can be subdivided into two categories. The first category of 
pathways repairs DSB and is comprised of the NHEJ and HR pathways. The second category 
repairs single strand breaks (SSB) and contains the nucleotide excision repair (NER), base 
excision repair (BER) and mismatch repair (MMR) pathways (Lord and Ashworth 2012; 
Shaheen, et al. 2011). BER repairs oxidative lesions, alkylation, small base adducts, and SSBs, 
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while NER repairs DNA helix disruptions caused by bulky adducts. MMR repairs dNTP 
misinsertions and 'insertion and deletion' loops that form during DNA replication. As discussed 
earlier, HR and NHEJ are involved in repairing DSBs and interstrand crosslinks (Shaheen, et al. 
2011). 
Table 4. Major DNA Repair Pathways 
 
Repair Pathway Lesion Key Proteins 
NHEJ Interstrand crosslink, DSB KU70/80, PRKDC 
HR Interstrand crosslink, DSB BRCA1, BRCA2, RAD51, 
ATM, ATR, CHEK1, CHEK2 
NER Bulky adducts, SSB ERCC1, ERCC4 
BER Uracil, Abasic site, SSB PARP1, XRCC1, LIG3 
MMR A-G mismatch, T-C 
mismatch, insertion, deletion, 
SSB 
MSH2, MLH1 
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1.6 CHEK1 INHIBITION AS A TARGETED CANCER THERAPY 
1.6.1 TARGETED CANCER THERAPY 
Targeted therapy against cancer has made substantial progress in the past decade. Specific gene 
mutations in cancer can lead to defects that can be targeted by drugs. The identification of 
genetic alterations as the cause of cancer has led to a major shift in cancer drug development. 
The aim of this evolution was to better target cancer cells, decreasing death of normal cells and 
eventually decreasing side effects.  
Targeted cancer strategies can be divided into two major categories. The direct 
‘conventional’ anticancer approaches that aims to inhibit or neutralize signaling pathways and 
‘synthetic lethality’ that aims to exploit the complex genetic defects of tumor cells (Ferrari, et al. 
2010). Conventional targeted approaches were launched in hematological cancers, such as CML 
where a distinct, unique BCR-ABL1 gene fusion is the driving cause of malignant growth 
(Druker, et al. 1996). Following the success of targeted therapy in CML and other hematological 
cancers, other targeted approaches were developed. Targeting the downstream effector proteins 
in cancer cells was also developed for use when direct inhibition is impossible. Examples of this 
approach include the targeting of the downstream effectors, KRAS, MEK in breast cancer and 
BRAF in melanoma (Garon, et al. 2010; Solit, et al. 2006). 
Cetuximab, an anti-EGFR targeted agent, is the only FDA-approved targeted therapy 
used in patients with OSCC (Simpson, et al. 2015). Cetuximab is used as an adjuvant therapy in 
primary or relapsed patients; especially patients who cannot tolerate platinum-based agents 
(Bonner, et al. 2010; Vermorken, et al. 2008). Cetuximab use in patients can be guided by EGFR 
expression studies, because patients with EGFR overexpression tend to have low OS (Ang, et al. 
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2002). Development of resistance to EGFR therapy is a major obstacle that needs to be addressed 
either through the development of other agents against EGFR or its downstream interacting 
targets, such as the PI3K pathway (Simpson, et al. 2015). Overall, it is clear that the development 
of other novel targeting approaches to OSCC is crucial. 
One of the promising targeted approaches that can be used in OSCC is agents that cause 
‘synthetic lethality.’ Synthetic lethality refers to the interaction of two genes, where a single 
genetic mutation is compatible with viability, but a combined genetic mutation is lethal (Ferrari, 
et al. 2010; Shaheen, et al. 2011). Synthetic lethality was first identified in yeast mutation 
screens, where the targeting of two mutations leads to an additive negative effect that 
compromises cellular function (Hannon 2002; Timmons 2006; Tong, et al. 2001). This 
unconventional targeted approach has a number of advantages. It spares normal cells because 
these cells do not have genetic mutations. It can also target the tumor cells if they have acquired 
either loss-of-function or gain-of-function mutations. Furthermore, it aids in the discovery of 
novel biomarkers and can be valuable in targeting cancer cells with ‘non-druggable’ pathway 
defects (Ferrari, et al. 2010). Disadvantages of synthetic lethality include the possibility of 
increasing the side effects of other cancer drugs and an increased risk of a shortened lifespan of 
effectiveness because of the development of resistance through other adaptation mechanisms 
(Shaheen, et al. 2011). 
The concept of synthetic lethality was shown to be extremely valuable in the 
manipulation of both the DDR and the cell cycle response. Cancer cells, unlike normal cells, 
acquire more genetic alterations and DNA damage post-therapy; this necessitates stopping at 
major cell cycle checkpoints to repair their DNA (Origanti, et al. 2013; Shaheen, et al. 2011).  
Most cancer cells lack an effective G1-S checkpoint and must arrest at the G2M checkpoint to 
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repair their genomes prior to cell division. Without efficient genomic repair at the G2M 
checkpoint, these cells would enter mitosis with damaged genomes and undergo ‘mitotic 
catastrophe’ (MC) (Shaheen, et al. 2011). Adding an agent that induces synthetic lethality 
through the abrogation of the G2M checkpoint would therefore spare normal cells which have a 
normal G1 checkpoint, which protects them against DNA damage-induced cell death (Origanti, 
et al. 2013). The concept of applying synthetic lethality in human tumor cells with defective 
DDR machinery was first shown in BRCA1- and BRCA2-deficient cells, where the defective HR 
caused by DSB made these cells susceptible to PARP1 inhibition (Bryant, et al. 2005; Farmer, et 
al. 2005). Overall, it is clear that targeted cancer approaches are gradually gaining more ground 
as possible adjuvant and neo-adjuvant therapeutic modalities in various cancers.  
1.6.2 CHEK1 INHIBITION 
Checkpoint kinase 1 (CHEK1), is an important downstream protein of ATR and is an important 
contributor to all of the cell cycle checkpoints, including the G1/S, intra-S-phase, G2/M, and the 
mitotic spindle checkpoint (Dai and Grant 2010). CHEK1 is activated through phosphorylation 
at Ser317/Ser345 (Sankunny, et al. 2014).  Unlike CHEK2, CHEK1 is activated by diverse 
stimuli that cause SSB in the DNA (e.g., UV, replication stresses, and DNA-damaging agents) 
through both ATR and ATM. On the other hand, CHEK2 activation is largely restricted to DSBs 
through ATM. In addition to the role of CHEK1 in cell cycle regulation, CHEK1 also regulates 
apoptosis independently of TP53, BCL2, and CASP3 (Sidi, et al. 2008). CHEK1 is also involved 
in the repair of mitotic defects through association with the kinetochores and phosphorylation at 
non-canonical sites in AURKB, thus enhancing its catalytic activity (Peddibhotla, et al. 2009). 
Given the important roles of CHEK1 in cell cycle regulation, maintenance of genomic integrity, 
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as a backup for CHEK2, mitotic defect repair and apoptosis; knocking out CHEK1 is a 
promising approach to cancer cell eradication (Bartek and Lukas 2003). 
The genes encoding components of the ATM/CHEK2 and the ATR/CHEK1 pathways 
are subject to frequent copy number loss in OSCC. This makes manipulation of the DDR to 
cause selective tumor cell death through MC partially effective in these tumors. Knocking out 
the G2M checkpoint using targeted CHEK1 inhibitors has been shown to cause ‘synthetic 
lethality’ because these cells would enter mitosis with damaged genomes and undergo MC 
(Origanti, et al. 2013; Parikh, et al. 2007). CHEK1 inhibitors have been successfully combined 
with DNA damaging agents in studies both in vitro and in vivo. The combination of CHEK1 
inhibitors and IR (Borst, et al. 2013; Ma, et al. 2012; Parikh, et al. 2013; Parikh, et al. 2007; 
Riesterer, et al. 2011; Sankunny, et al. 2014) or chemotherapy (Blasina, et al. 2008) has been 
shown to be effective in a variety of carcinomas. PF-00477736 is a CHEK1 small molecule 
inhibitor (SMI) developed by Pfizer that our group has used successfully to potentiate the effect 
of IR (Sankunny, et al. 2014). PF-00477736 also shows a synergistic effect when combined with 
inhibitors of the DNA repair enzyme, poly (ADP-ribose) polymerase (PARP) in a number of 
breast and pancreatic cancer cell lines (Mitchell, et al. 2010). Recent results have shown different 
effectiveness as regards to the combination of gemcitabine and CHEK1 inhibitors in CSLC in 
from NSCLC (Bartucci, et al. 2012; Fang, et al. 2013). Studying the effects of CHEK1 inhibitors 
on OSCC CSLCs is a new promising focus of research and is one of the main objectives of our 
project. 
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2.0  MATERIALS AND METHODS 
2.1 CELL CULTURE 
2.1.1 OSCC cell lines 
In order to study CSLC markers in OSCC, low passage (<20) UPCI:SCC cell lines: 
UPCI:SCC029B, SCC040, SCC056, SCC066, SCC078, SCC084, SCC099, SCC103, SCC104, 
SCC114, SCC116, SCC122, SCC125, SCC131, SCC136, SCC143, SCC172, SCC182 were 
cultured. We then selected nine OSCC cell lines with or without distal 11q loss for additional 
studies: UPCI:SCC029B, SCC040, SCC104, SCC066, SCC081, SCC116, SCC122, SCC125 and 
SCC131. The entire set of UPCI:SCC cell lines was established previously in our laboratory 
(White, et al. 2007). The UPCI:SCC oral cell lines were cultured in M10 medium comprised of 
Minimal Essential Medium (MEM) supplemented with 1% non-essential amino acids (NEAA), 
1% L-glutamine, 0.05 mg/ml gentamicin and 10% fetal bovine serum (FBS) (all from GIBCO 
Invitrogen, Grand Island, NY). For subculturing OSCC, adherent cells were detached from the 
flask surface by trypsinizing with 0.05% trypsin/0.02% EDTA (Irvine Scientific) for 3–5 min at 
37oC in a humidified 5% CO2 incubator. An equal amount of M10 medium was used to inhibit 
trypsin activity following detachment and cells were replated.  
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2.1.2 Control cell line 
TERT-transfected human oral keratinocytes (OKF6/TERT-1 cells), a gift from Dr. James 
Rheinwald, Brigham and Women's Hospital, Harvard Institutes of Medicine (Dickson, et al. 
2000) were cultured in Keratinocyte-SFM supplemented with 25 μg/ml bovine pituitary extract, 
0.2 ng/ml EGF, 0.3 mM CaCl2, and penicillin-streptomycin (GIBCO Invitrogen). 
2.1.3 CSLC cell cultures 
In order to study CIN in CSLC, CSLC cell cultures HNSCC#13 and HNSCC13 (E8) kindly 
provided by Dr. Eric Lagasse were used. CSLCs were plated on a stromal monolayer of 
previously irradiated (80 Gy) rodent epithelial feeder cells (Odoux, et al. 2008) or Matrigel™ -
coated plates (BD, Franklin Lakes, NJ).  
2.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 
2.2.1 Assessment of ATM copy number alterations 
In order to study the copy number status of ATM, and to classify cell lines as ‘distal 11q loss’ or 
‘No distal 11q loss’ FISH was done. A single colony of E. coli carrying the individual BAC 
(mapping to ATM; BAC ID: CTD2047A4) was incubated overnight at 37oC in 5 ml of Luria–
Bertani (LB) medium with 50 µg/ml Chloramphenicol. The bacteria were centrifuged at 10,000 x 
g for 30s. The bacteria were resuspended in 100 µl of STET (8% sucrose, 5% Triton X100, 
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50mM EDTA, 50 mM Tris pH 8.0). Freshly prepared alkaline SDS (0.2 M NaOH, 1% SDS) was 
added to lyse the bacteria and the solution was incubated at 24oC for 2 min. Cold ammonium 
acetate (4oC) was added and the solution was incubated for 5 min on ice. Following this step, the 
bacteria were centrifuged at 4oC for 15 min at 16,000 x g. Equal amounts of phenol and 
chloroform were added to the supernatant to extract the DNA. The top layer of the mixture was 
treated with 0.6 x volume of isopropanol and centrifuged at 4oC for 15 min at 16,000 x g. The 
supernatant was drained and the pellet washed with 70% ethanol and air dried. The DNA was 
resuspended in 100– 200 µl of Tris–EDTA (TE) buffer (QIAGEN, Valencia, CA) and stored at 
4oC. In order to prepare mitotic cells for FISH analyses, OSCC cells were harvested following 5 
hr of 0.1μg/ml Colcemid™ (Irvine Scientific, Santa Ana, CA) treatment, hypotonic KCl (0.075 
M) treatment for 15 min and fixation in 3:1 methanol:glacial acetic acid. For FISH analysis, cells 
were harvested, dropped onto slides, treated with RNase/2xSSC (saline sodium citrate), and 
dehydrated using serial treatments with 70%, 80% and 100% ethanol. Chromatin was denatured 
with 70% formamide and dehydrated in 70%, 80% and 100% ethanol. The ATM BAC probe 
clone for FISH, was obtained from Children’s Hospital of Oakland Research Institute (CHORI, 
Oakland, CA) and labelled with Spectrum OrangeTM. Using a nick translation kit from Vysis, 
Inc. (Abbott molecular Inc, Des Plaines, IL), extracted DNA was precipitated with ethanol, 
resuspended in hybridization buffer, centromere enumeration probe for chromosome 11 labelled 
with Spectrum GreenTM (Abbott Molecular Inc., Des Plaines, IL.), and allowed to pre-anneal for 
1-2 h at 37oC. The probe was hybridized to the slides for 16 h at 37oC, after which slides were 
washed with SSC/Tween-20. Slides were counterstained with 4',6-diamidino-2-phenylindole 
(DAPI, 160 ng/ml 2xSSC) and mounted with antifade (comprised of 1 mg/ml 1,4-phenylene-
diamine (Sigma-Aldrich, St. Louis, MO) prior to analysis.  All FISH analyses were carried out 
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using an Olympus BX61 epiflorescence microscope (Olympus Microscopes, Melville, NY). An 
Applied Imaging CytoVision workstation with Genus v3.6 software was used for image capture 
and analysis (Leica Microsystems, San Jose, CA). 
2.2.2 Assessment of Chromosomal Instability in CSLC  
In order to study the copy number status of different chromosomes (Chromosomes 4, 6, 7, 9 and 
20), FISH was done on CSLC isolated from HNSCC#13 and HNSCC#13 (Clone E8). These 
experiments were done by DL and analyzed by HK. Centromere enumeration probes for 
chromosomes: chromosome 4 (p4n1/4), chromosome 6 (pEDZ6), chromosome 7 (pZ7.5), 
chromosome 9 (pMR9A) and chromosome 20 (pZ20) were purchased from Vysis, Inc. (Abbott 
molecular Inc, Des Plaines, IL). Centromeric probes were labelled with the following the 
fluorochromes, Chromosome 4 spectrum orange (SO), Chromosome 6 spectrum green (SG), 
Chromosome 7 (SG), Chromosome 9 (SG), Chromosome 17 (SO) and Chromosome 20 (SO). 
FISH was done as previously described. 
2.3 IMMUNOFISH 
To study ATM copy number status in CSLC (CD133+) and non-CSLC (CD133-) from OSCC 
cell lines immuno-FISH was done. Slides were stained with CD133 (1:200, 19898, Abcam) (as 
described in the IF section) prior to FISH hybridization. Coverslips were removed and washed 
with 2xSCC 15 min at RT (room temperature) followed by dehydration in a graded series of 
70%, 85% and 100% ethanol to dehydrate them. The FISH probe that localizes to the ATM 
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region of chromosome 11 labelled with Spectrum Orange and CEP11 labelled with Spectrum 
Green (Abbott Molecular Inc, Des Plaines, IL) were mixed with 70% hybridization buffer. The 
probe set was pre-denatured at 75° C for 5 minutes and preannealed at 37° C for 15 minutes. The 
probe mixture was applied to the slide, coverslipped and codenatured at 75°C for 5 minutes. The 
slide was allowed to hybridize in a humidified chamber at 39°C overnight. The following day, 
the slide was washed free of the unbound probe with a 2xSSC/0.1% Tween-20, stained with 
DAPI, and mounted with ProLong Gold Antifade Reagent (P10144, Life Technologies Carlsbad, 
CA). All immuno-FISH analyses were carried out using an Olympus BX61 epifluoresence 
microscope (Olympus Microscopes, Melville, NY). An Applied Imaging CytoVision workstation 
with Genus v3.6 software was used for image capture and analysis (Leica Microsystems, San 
Jose, CA).  
2.4 SPHEROID ENRICHMENT ASSAYS 
To study the different CSLC properties, spheroid enrichment was used. Two approaches were 
used for enrichment, an adherent and a non-adherent approach. For the adherent approach, 
enriched CSLC were grown on Matrigel™ -coated plates (BD, Franklin Lakes, NJ). For the non-
adherent (suspension) approach spheroids were grown in ultra-low attachment six-well plates 
(Corning, NY). OSCC cell lines were dissociated with accutase (A11105-01, Life Technologies 
Carlsbad, CA) and pipetted with a 10 ml pipette, cell aggregates were washed twice with 
phosphate buffered saline (PBS), centrifuged and dissociated by pipetting into a single cell 
suspension. The single cell suspension was placed under stem cell suspension culture conditions, 
which consisted of serum-free Dulbecco's minimum essential (DMEM/F12) medium 
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supplemented with N2 supplement (17502-048, GIBCO, Grand Island, NY), B27 (17504-044, 
GIBCO), L-glutamine (25030-149, GIBCO), Gentamicin (20 mg/ml, GIBCO),  human 
recombinant epidermal growth factor (EGF; 20 ng/ml, Sigma-Aldrich), and human basic 
fibroblast growth factor (bFGF; 20 ng/ml Sigma-Aldrich) (Lim, et al. 2011). 
2.5 SPHEROID SELF-RENEWAL ASSESSMENT 
Primary/secondary spheroid enrichment comparative analysis was done to assess the self-
renewal capacity of the enriched CSLC. Equal numbers of cells derived from OSCC cell lines 
(primary) and enriched spheroids (secondary) were suspended in SC medium (as described 
earlier). Individual primary non-adherent spheroids were selected using a 37 µm Reversible 
Strainer (Stem cell technologies, BC, Canada), centrifuged at 1400 rpm for 4 min, and then 
mechanically dissociated and re-plated (Molofsky, et al. 2003). Large spheroids (more than 100 
cells) were counted and photographed on a phase contrast microscope (Leica Microsystems, 
Germany).  
2.6 SPHEROID SURVIVAL ASSAY 
To assess the radioresistance of CSLC from OSCC cell lines with and without distal 11q loss, 
spheroid survival was carried out. 5*104 cells were plated in triplicate in ultra-low attachment 
six-well plates in spheroid enrichment medium. After 7–11 days in culture, colonies with >50 
cells were counted. For IR-induced damage studies, cells were then treated with 2.5 or 5 Gy 
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doses of γ-irradiation from a Gammacell 1,000 Elite Irradiator (Nordion International, Ottawa, 
Canada) with a 137Cs source at a dose rate of 2.83 Gy/min. All experiments were performed in 
triplicate. Results were reported as the ‘Surviving Fraction’ which is the ratio of the number of 
spheroids observed at a particular dose to that observed in the untreated control, represented as a 
percentage. It is calculated using the following formula: 
Surviving Fraction, SF = (spheroids counted in treated / spheroids counted in untreated) * 100 
2.7 SPHEROID GROWTH ASSAY 
To assess the effect of IR on spheroid growth, spheroid growth was assessed. 2000 cells were 
plated in agarose-coated 96-well plates. Post-IR, the wells were imaged using a phase contrast 
microscope (Leica Microsystems, Germany) and spheroids were analyzed using ImageJ for size 
differences in response to IR (NIH, Bethesda, MD). 
2.8 SPHEROID MIGRATION ZONE ASSESSMENT 
To determine the effect of IR and combined IR and CHEK1 SMI on spheroids, the spheroid 
migration zone was assessed. Spheroid migration zone assessment was modified from that 
described by Vinci et al. (Vinci, et al. 2013). A fixed endpoint (96 hrs post-plating) was utilized. 
Non-adherent spheroids were grown as described previously. Plates were coated with Matrigel™ 
(BD, Franklin Lakes, NJ) for at least 2 hr before use. The spheroids were grown in enriched SC 
medium and then centrifuged at 900xg for 30 minutes and allowed to attach on Matrigel-coated 
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plates overnight. Four days post-treatment, plates were fixed with 70% ethanol and stained with 
Giemsa (Sigma, St. Louis, MO). Plates were then photographed (Leica Microsystems, Germany) 
and spheroid migration zone analysis was carried out using ImageJ (NIH, Bethesda, MD). The 
area covered by the spheroids at t= 0 hr and the area covered by the cells that have migrated from 
the spheroids at t = 96 hr was determined. Data were normalized to the original spheroid 
recorded using the following formula: 
% migration = (migrated area (t = 96 hr) / original spheroid (t = 0 hr)) × 100. 
2.9 CLONOGENIC COLONY SURVIVAL ASSAY 
Clonogenic survival assays were carried out to determine cell survival in response to treatment as 
standardized previously in our lab (Parikh, et al. 2007). Two thousand cells were seeded in 60 
mm Petri dishes and allowed to adhere overnight. Cells were then treated with increasing doses 
of γ-irradiation at 2.5 and 5 Gy using Gammacell 1000 Elite irradiator (Nordion International, 
Inc., Ottawa, Canada) with a 137Cs source at a dose rate of 2.83 Gy/min. The culture medium was 
replaced at the end of 7th day. Untreated cells cultured in parallel were used to determine relative 
plating efficiency and to standardize the treatment plates. After 10-14 days, the plates were fixed 
with 70% ethanol and stained with Giemsa (Sigma, St. Louis, MO) and the number of colonies 
was counted.  A colony was defined as a cluster of ≥50 cells, having formed from a single cell. 
All experiments were performed in triplicate, and the error reported as one standard deviation 
from the mean. 
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2.10 IMMUNOFLUORESCENCE (IF) 
2.10.1 Adherent IF 
IF was used to determine whether cells in OSCC cell lines express CSLC markers. 75*103 cells 
were cultured on square (25mm) coverslips (Thermofisher Scientific, MA) in order to reach a 
confluency of 75%. The coverslips were then rinsed with 1xPBS and fixed in 4% 
paraformaldehyde (PF)/1x PBS for 15 minutes in RT. For nuclear/cytoplasmic staining, 
coverslips were washed with 0.2% Triton X-100/1x PBS; for membrane staining, coverslips 
were washed with 1xPBS. Cells were then blocked with blocking buffer (1% Bovine serum 
albumin (BSA) or 3% Rabbit serum, 0.2 M Glycine or Image iT FX signal enhancer (Life 
Technologies) for 30 - 60 min. Immunostaining with antibodies against CD44 (1:100, 550392, 
BD), CD133 (1:200, 19898, Abcam), CD133/1(AC133) (1:10, 130-090-422, Miltenyi Biotec), 
BMI1 (1:400, 6362A, Imgenex), BMI1 (1:400, 14389, Abcam), SOX2 (1:400, 6507A, Imgenex), 
NESTIN (1:400, 6492A, Imgenex) was carried out at RT for 1 hr. After washing, cells were 
incubated with secondary antibodies, Goat antimouse Alexa Fluor 488 (1:500, A-11001, Life 
Technologies) and/or Goat Anti-Rabbit Alexa Fluor 546 (1:500, A-11010, Life Technologies). 
Nuclei were counterstained with DAPI and mounted with ProLong Gold Antifade Reagent 
(P10144, Life technologies). Slides were photographed using a confocal fluorescence 
microscope (Leica Microsystems, Germany).  
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2.10.2 Suspension IF 
Suspension IF was used to assess CSLC in non-adherent spheroids. Spheroids were enriched as 
described earlier. The spheroid suspension was transferred into a microcentrifuge tube and 
centrifuged at 800 xg for 3 min and re-suspended in 1 ml PBS. The spheroid suspension was 
centrifuged at 800 xg for 3 min, and the supernatant was then discarded. The spheroid pellets 
were re-suspended in 160 µl 1xPBS/20 µl 37% PF for 10 min. Spheroid suspensions were 
centrifuged, PF was then discarded, and the pellet was re-suspended in 1 ml 1xPBS. The 
spheroid pellet was permeabilized with 0.3% Triton X-100/1x PBS for 10 min, centrifuged at 
800 xg for 3 min, and the supernatant was then discarded. The spheroid pellet was blocked with 
blocking buffer (1% Bovine serum albumin (BSA) or 3% Rabbit serum, 0.2 M Glycine or Image 
iT FX signal enhancer (Life Technologies) for 30 - 60 min at RT. The spheroid suspension was 
centrifuged at 800 xg, the supernatant was then discarded, and the pellet was mixed with 100 µl 
primary antibody ((CD44 (1:100, 550392, BD), CD133 (1:200, 19898, Abcam), BMI1 (1:400, 
6362A, Imgenex) or SOX2 (1:400, 6507A, Imgenex)), thermo-mixed for 30 sec, and then 
incubated at RT for 1 hr. The spheroid suspension was centrifuged at 800 xg, the supernatant was 
then discarded and the pellet was washed three times with 1xPBS. 100 µl secondary antibody, 
Goat antimouse Alexa Fluor 488 (1:500, A-11001, Life Technologies) or Goat Anti-Rabbit 
Alexa Fluor 546 (1:500, A-11010, Life technologies) was added to the spheroid pellet and 
themo-mixed for 30 sec and then incubated at RT for 1 hr. The spheroid suspension was 
centrifuged at 800 xg, the supernatant was then discarded, and the pellet was washed three times 
with 1xPBS. Cells were counterstained with DAPI for 5 min at RT. Spheroid suspension was 
centrifuged at 800 xg, supernatant was then discarded and the pellet was mounted with ProLong 
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Gold Antifade Reagent (P10144, Life Technologies). Slides were photographed using a confocal 
fluorescence microscope (Leica Microsystems, Germany). 
2.11 IMMUNOFLUORESCENCE ASSESSMENT 
The intensity of fluorescence was scored as follows: 0-50% as 1 (+), 50-80% as 2 (++) and 
>80% as 3 (+++); negative staining was scored as 0. CSLC were identified as the 3 (+++) 
subpopulation in the sample. Random slides were scored by a second researcher, MB; and more 
than 85% correlation was observed.   
2.12  IMMUNOFLUORESCENCE ASSESSMENT OF GAMMA-H2AX, KU70 AND P-
CHEK1 FOCI  
IF staining for H2AX, KU70 and pCHEK1 foci was used to assess the DDR in CSLC.  Foci were 
analyzed 1 hr after exposure to 2.5 Gy IR using Gammacell 1,000 Elite Irradiator (Nordion 
International, Ottawa, Canada) with a 137Cs source at a dose rate of 2.83 Gy/min. Dissociated 
CSLC from enriched spheroids or adherent enriched CSLC were attached to coverslips prior to 
treatment with IR. Control slides, which were untreated (0 Gy), were prepared for each cell line. 
Following exposure to IR, the cells were washed with 1x HBSS (Corning, New York), the 
medium replaced, and the coverslips incubated under standard culture conditions for 1 hr to 
allow for repair. After 1 hr, the cells were washed with 1x PBS, fixed with 4% PFA (Sigma, St. 
Louis, MO) for 30 min and permeabilized with 0.2% Tritonx100/1x PBS. Following 
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permeabilization, cells were blocked with 2% BSA and incubated with anti-gamma-H2AX 
primary antibody (1:1000, 22551, Abcam), KU70 (1:100, 611892, BD) or p-CHEK1 (1:100, 
2348S, Cell Signaling) for 1 hr. The secondary antibody used was a Goat Anti-Rabbit Alexa 
Fluor 546 (1:500, A-11010 , Life Technologies) or antimouse Alexa Fluor 488 (1:500, A-11001, 
Life Technologies) for 1 hr. Cells were then washed, counterstained with DAPI, mounted using 
ProLong Gold Antifade Reagent (P10144, Life Technologies), and analyzed under an 
epiflorescence/confocal microscope as described earlier. A minimum of 500 cells were scored 
from control and IR-treated coverslips for each of the cell lines. 
2.13 FLOW CYTOMETRY FOR CELL SURFACE MARKER ASSESSMENT 
Flow cytometry was used to study CSLC surface markers in OSCC cell lines. Cells were 
harvested, counted and suspended in ice cold PBS, 10% FCS, 1% sodium azide at 1.5 x 
106 cells/ml per well in 96 well round bottomed microtiter plates (100 μl/well). Plates were 
centrifuged at 400 xg for 5 minutes and washed with monoclonal wash (Hanks, 2% FGS and 
0.1% sodium Azide). Cells were stained with conjugated monoclonal antibodies: CD44 Mouse 
monoclonal CD44 FITC (BD, Franklin Lakes, NJ) or CD133/1 (AC133)-PE (Miltenyi Biotec, 
Bergisch Gladbach, Germany) prepared in ice cold reagents/sodium azide, at the appropriate 
dilution (Appendix B) for 30 minutes. Unstained controls were prepared by omitting the staining 
step. Dead cells were detected with propidium iodide (10 μg/mL). The cells were washed twice 
by centrifugation at 400 xg for 5 minutes and re-suspended in 500 µl to 1 ml of ice cold PBS, 
10% FBS, 1% sodium azide. The cells were kept in the dark on ice or at 4°C in a refrigerator 
until the scheduled time for analysis. For extended storage, cells were fixed in 4% PF to prevent 
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deterioration. Post-acquisition analysis of the fluorescence-activated cell sorting data and 
desktop publishing were accomplished using the third-party flow cytometry software FlowJo 
(Tree star, Ashland, Oregon). 
2.14 DIFFERENTIATION ASSAY 
To determine the differentiation potential of enriched CSLC cells, spheroids were dissociated by 
pipetting  and cultured in M10 medium on Matrigel™ -coated plates without supplemental 
growth factors (GF) in the presence of 10% serum (Ricci-Vitiani, et al. 2007). 
2.15 CELL CLONING BY SERIAL DILUTION 
Serial dilution was used to isolate clones from OSCC cell lines that originated from a single cell 
per well. These experiments were done by HK and MB. For this study, the cell line 
UPCI:SCC125 was used to isolate cell clones with and without distal 11q loss.  UPCI:SCC125 is 
a unique cell line showing approximately 50% 11q loss (Parikh, et al. 2007). Serial dilution was 
done in a 96-well plate, single colonies were then dissociated and transferred sequentially to 12-
well plates, 6-well plates and T25 flasks. The clones were then assessed by FISH for ATM status.  
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2.16 EXTREME LIMITING DILUTION ASSESSMENT 
The aim of extreme limiting dilution assessment is to study the SC frequency in cultures and to 
determine the clonogenic potential of CSLC in response to therapeutic interventions. 96-well 
plates coated with agarose as described by Friedrich et al. (Friedrich, et al. 2009) and spheroid 
medium were used. A 2 ml cell suspension containing 20,000 viable cells was prepared. 200 
μl/well were loaded in row A (columns 1-12) and 100 μl was loaded in other well row B-H 
(columns 1-12). Serial dilution was done down row B through to row H. Plates were assessed for 
spheroid formation in 7-10 days post plating. Analysis of CSLC was done using CSLC analysis 
software (Hu and Smyth 2009). 
2.17 MITOTIC CELL COLLECTION AND ANALYSIS 
To assess mitotic cell division, slides were prepared using the following approach. A method 
increasing the mitotic division was used modified from that described previously by Lathia et al. 
was used (Lathia, et al. 2011). Adherent cultures grown on Matrigel™-coated coverslips in M10 
medium were enriched with 2mM thymidine for 48 hr. Cells were then cultured for 12 hr in M10 
medium without thymidine. After washing with 1x PBS, mitotic cells were shaken off the plates 
by vortexing for 30 s. Detached cells were collected and settled onto Matrigel™-coated 
coverslips at the bottom of the 6-well plates using centrifugation at 200 xg. for 15 min at RT 
(room temperature). Cells were then stained with DAPI or an IF marker as described previously. 
Fluorescence images were acquired using a confocal microscope (Leica Microsystems, 
Germany); images were processed and assembled using ImageJ (NIH, Bethesda, MD). To 
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quantify the degree of asymmetric:symmetric distribution of the CSLC marker between the two 
daughter cells, the intensity of fluorescence was assessed for each daughter cell. Images of 
intermediate/late anaphase to telophase were collected for assessment. The dividing daughter 
cells were defined by the condensed DNA detected by DAPI staining. Each identified daughter 
cell in a dividing pair was marked with the freehand tool, and the fluorescent signals of the 
defined daughter cells were determined for the CSLC markers. In order to classify the division 
type, percentage (%) difference was calculated as follows: F= (F1-F2/F1+F2)*100; where F1 and 
F2 represent the fluorescent values of a given stain for two dividing daughter cells. The 
asymmetric cutoff was set based on the evaluation of a cluster analysis as in similar previous 
studies (Lathia, et al. 2011). 
2.18 CHROMOSOMAL SEGREGATION DEFECTS ASSESSMENT 
CSD assessment was used to assess the segregation defects post-IR in CSLC (SOX2+) and non-
CSLC (SOX2-). We analyzed mitotic defects in OSCC cell lines grown on Matrigel™-coated 
coverslips. Cells were either untreated or treated with 2.5 Gy and then grown for 36 hours. At the 
end of the 36 hours, the cells were fixed with 4%PF/1xPBS, dried, and IF stained with SOX2 as 
previously described. Coverslips were mounted onto slides with ProLong Gold Antifade 
Reagent. More than 1000 cells were analyzed from each cell line. The frequencies of anaphase 
and interphase bridges, unclassifiable defects and micronuclei were recorded. The values for cell 
lines were averaged and grouped into two categories, ‘CSLC’ and ‘Non-CSLC.’ 
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2.19 CELL VIABILITY ASSAY 
Cell survival/viability assays assessed the survival of CSLC post-intervention. Two methods 
were used, the first using a Live/Dead Viability/Cytotoxicity Kit and the second involved using 
trypan blue exclusion.  
2.19.1 Live/Dead Viability/Cytotoxicity Kit 
Viability assays were done using the LIVE/DEAD Reduced Biohazard Viability/Cytotoxicity Kit 
L-7013 (Thermo Fisher Scientific, Carlsbad, CA). Cells were attached to sterile glass coverslips, 
treated with IR, and stained 72 hrs after the treatment. Culture medium was removed and cells 
were washed with HBSS. A mixture of SYTO 10 green fluorescent nucleic acid stain 
(Component A) and ethidium homodimer-2 nucleic acid stain (Component B) were diluted in 
HBSS (1:500 dilution of each). 200 µL was applied to each coverslip, and then incubated in the 
dark for 15 minutes. Coverslips were then washed twice with HBSS. Coverslips were then 
incubated with 4% Paraformaldehyde for 30 minutes. Coverslips were then mounted to slides 
using ProLong Gold Antifade Reagent, and analyzed under a epiflorescence/confocal 
microscope (Leica Microsystems, Germany). 
2.19.2 Cell viability Assay using Trypan Blue Exclusion 
Equal volumes of cell suspension and 0.4% trypan blue (15250-061, Life Technologies) were 
thoroughly mixed and assessed using a hemacytometer. Cell viability was calculated as the 
number of viable cells divided by the total number of cells within the grids on the 
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hemacytometer.  If cells stained blue due to uptake of trypan blue, they were considered non-
viable. 
2.20 STATISTICAL METHODS 
2.20.1 General statistical methods 
All studies were done in triplicate and results compared by the most appropriate statistical 
methods. A biostatistician was consulted to verify the methods used in the analysis. Most data 
are presented as the mean ± SEM, unless otherwise specified. Any p value < 0.05 was considered 
statistically significant. 
2.20.2 Assessment of prognostic significance of CSLC markers in OSCC  
Correlation of CSLC markers with various prognostic factors was done to investigate the 
possible role of CSLC in OSCC prognosis. To assess the prognostic significance of CSLC 
markers (CD44, CD133, SOX2 and BMI1), patients were grouped based on clinical covariates of 
interest as categorical variables (histological grade, T, N and TNM staging, smoking, HPV and 
TP53) and CSLC expression (high/low). Fisher’s exact test was used to assess the statistical 
significance within the two groups based on the sample size; p values < 0.05 were considered 
statistically significant. Statistical analyses were performed using the SAS System for Windows, 
Version 9.2 (SAS Institute Inc., Cary, NC). Tumor size and CSLC marker expression were 
analyzed as continuous values. Pearson's correlation was then used to calculate the correlation 
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coefficient between tumor size and CSLC marker positive group. For survival analysis, CSLC 
expression of CD44, CD133, SOX2 and BMI1 was grouped into CSLC high and CSLC low 
groups. Kaplan–Meier survival statistics were used to evaluate OS (time from definitive cancer 
treatment to death of any cause) among CSLC high and low. Any p value < 0.05 was considered 
statistically significant.  
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3.0  RESULTS 
3.1 CSLC MARKERS IN OSCC CELL LINES 
 
3.1.1 CSLC markers in OSCC cell lines 
To determine the expression of CSLC markers in a group of 18 OSCC cell lines we utilized IF 
(Table 5); our main objective was to assess which markers could be further used in investigating 
the properties of CSLC and to assess the prognostic significance of CSLC markers. The OSCC 
cell lines expressed CSLC markers variably, suggesting the possible role of these markers in 
prognosis (Figures 8-16). There was no statistical difference between OSCC cell lines with distal 
11q loss (UPCI:SCC029B and SCC040) and no distal 11q loss (UPCI:SCC066 and SCC116) 
based of CSLC marker (Figure 9). Positive (+++) CD44 and BMI1 were expressed at higher 
rates (23 and 16% respectively) when compared to CD133/1 and SOX2 (6 and 6% respectively). 
Flow cytometric analyses of four OSCC cell lines revealed that the proportion of CD44+ cells 
was uniformly high; CD133/1 was inconsistent on replication (Figure 16). Double IF staining 
with different CSLC markers demonstrated that only ≈1-3% of the cells co-express the CSLC 
marker (Figures 13, 14). Assessing CSLC markers in a normal oral epithelial cell line (OKF6) 
showed that CD133/1, SOX2 and BMI1 are not expressed; only CD44 was expressed (Figures 
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12, 13). Overall, our results suggest that CSLC markers (CD133/1, SOX2 and BMI1) are 
overexpressed in a cancer cells. Furthermore, double IF of OSCC with CSLC markers has 
yielded high correlative evidence that a subpopulation of cells exists in our cell lines with SC 
potential (Figures 14, 15). Our results have also indicated that CD133/1 and SOX2 may be 
promising CSLC markers in OSCC. 
Table 5. Measures of Central Tendency of CSLC-Positive (+++) Cells in UPCI:SCC Cell 
lines* as assessed by IF 
 
  MEAN MODE MEDIAN 
CD44 23.11111 15 21 
CD133/1 6.444444 9 5.5 
SOX2 6.8125 6 6 
BMI1 16.27778 16 14.5 
 
* UPCI:SCC cell lines investigated: UPCI:SCC029B, SCC040, SCC056, SCC066, SCC078, 
SCC084, SCC099, SCC103, SCC104, SCC114, SCC116, SCC122, SCC125, SCC131, SCC136, 
SCC143, SCC172, SCC182. 
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Figure 8. IF staining of UPCI:SCC029B with CSLC surface markers  
 
 
 
Figure 9. Frequencies of positive cells as assessed by CSLC surface markers  
No statistically significant difference is observed in the frequency of cells positive for CSLC 
markers between OSCC with distal 11q loss (UPCI:SCC029B and SCC040) and without distal 
11q loss (UPCI:SCC066 and SCC116). 
 65 
 
Figure 10. IF staining of UPCI:SCC029B with CSLC markers 
 
 
 
Figure 11. Frequencies of positive cells as assessed by CSLC markers 
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Figure 12. IF of the control cell line, OKF6 with CSLC markers 
 
 
 
Figure 13. Frequencies of positive cells as assessed by CSLC markers in the control cell 
line, OKF6  
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Figure 14. Double IF staining of UPCI:SCC029B with CSLC markers 
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Figure 15. Double IF staining of OSCC cell lines utilizing CSLC marker combinations 
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Figure 16. Flow cytometric analysis of OSCC tumor cells isolated and cultured under 
identical conditions 
A. Change in fluorescence intensity was measured by flow cytometry for unlabeled cells 
(blue peaks) and cells labeled with CD44 (red peaks). Gated runs were analyzed with 
FlowJo modeling software (Left to Right: UPCI:SCC029B, UPCI:SCC040, 
UPCI:SCC066 and UPCI:SCC116). 
B. Change in fluorescence intensity was measured by flow cytometry for unlabeled cells 
(blue peaks) and cells labeled with CD133/1(red peaks). Gated runs were analyzed with 
FlowJo modeling software (Left to Right: UPCI:SCC029B, UPCI:SCC040, 
UPCI:SCC066 and UPCI:SCC116). 
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C. Table showing the summarized results of flow cytometric analyses of each cell line (HM, 
Homogenous high staining; HT, two distinct population; N, Negative for the marker; IN, 
determined inconsistent among the replicates studied). 
3.1.2 Prognostic significance of CSLC markers in OSCC cell lines 
We assessed the prognostic significance of CSLC markers (CD44, CD133/1, SOX2 and BMI1) 
by IF in a panel of 18 OSCC low passage cell lines, previously established in our Lab (White, et 
al. 2007). Cut-offs for CD44, CD133/1, SOX2 and BMI1 in all 18 OSCC specimens were 
estimated based on previous literature (Chinn, et al. 2015; Joshua, et al. 2012) and the median for 
each marker (23%, 5%, 5% and 16%, respectively; Table 5) and categorized as high or low 
based on the frequency of positive cells (+++). Tumor grading was classified as early (stages 
I/II) or advanced stage tumors (stages III/IV).  Lymph node staging was classified as negative 
(N0) or positive (N1, N2). Histological differentiation was classified as differentiated, 
moderately differentiated or poorly differentiated. Smoking and HPV status were each classified 
as positive or negative.  
We did not find prognostic significance between CSLC marker and tumor grade, LN 
positivity, histological differentiation, recurrence/relapse, smoking, HPV status, tumor size and 
TP53 status (p>0.05)(Table 6). Tumor specimens were analyzed for association between CSLC 
marker and recurrence/relapse. Patients who developed recurrence/relapse had higher CD44-high 
compared to patients with CD44-low cell lines; however, this was not statistically significant 
(CD44: 58% vs 50%; p>0.05). CD133/1-high, SOX2-high and BMI1-high did not show a 
statistically significant relationship with recurrence or relapse (CD133/1: 67% vs 67%, p>0.05; 
SOX2: 58% vs 60%, p>0.05; BMI1: 42% vs 67%, p>0.05) 
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Analysis of patient survival outcomes relative to CSLC markers was performed (Figure 
17). There was no difference in OS (CD44 p>0.05; CD133/1 p>0.05; SOX2, p>0.05; BMI1, 
p>0.05) between patients with CSLC high compared to those with CSLC low. 
 
Table 6. Prognostic significance of CSLC marker in a group of 18 OSCC cell linesa 
 
CD44 SOX2 BMI1 CD133
Range 2-63% 2-18% 2-39% 2-12%
Characters High positive cases (%) P value High positive cases (%) P value High positive cases (%) P value High positive cases (%) P value
T grade
T1/T2 4/11(36%)  p > 0.05 5/11(45%)  p > 0.05 4/11 (36%)  p > 0.05 6/11 (55%)  p > 0.05
T3/T4 4/7 (57%) 5/6(83%) 5/7 (71%) 6/7 (86%)
N grade
N0 5/9 (56%)  p > 0.05 5/9(56%)  p > 0.05 4/9 (44%)  p > 0.05 5/9 (56%)  p > 0.05
N1/2 2/5 (40%) 4/7(57%) 5/8 (63%) 7/8 (88%)
Histology
Well 1/2 (50%)  p > 0.05 1/2(50%)  p > 0.05 1/2 (50%)  p > 0.05 1/2 (50%)  p > 0.05
Moderate 7/12 (58%) 7/11(64%) 6/12 (50%) 9/12 (75%)
Poor 1/2 (50%) 1/2(50%) 2/2 (100%) 1/2 (50%)
Tumor size
0.4264  p > 0.05  0.2331  p > 0.05  0.1835  p > 0.05 0.2334  p > 0.05
Weak +ve correlb Weak +ve correlb Weak +ve correlb Weak +ve correlb
Recc/relc
N0 3/6 (50%)  p > 0.05 3/5(60%)  p > 0.05 4/6 (67%)  p > 0.05 4/6 (67%)  p > 0.05
YES 7/12 (58%) 7/12(58%) 5/12 (42%) 8/12 (67%)
Smokingd
N0 1/2 (50%)  p > 0.05 1/2(50%)  p > 0.05 1/2 (50%)  p > 0.05 2/2 (100%)  p > 0.05
YES 8/15 (53%) 8/14(57%) 7/15 (47%) 9/15 (60%)
HPVd
N0 9/17 (53%)  p > 0.05 9/16(56%)  p > 0.05 8/17 (47%)  p > 0.05 11/17 (65%) p > 0.05
YES 1/1 (100%) 1/1(100%) 1/1 (100%) 1/1 (100%)
TP53 statuse
Wild 1/5(20%)  p > 0.05 4/5(80%)  p > 0.05 3/5(60%)  p > 0.05 3/5(60%) p > 0.05
Mutant 7/13(54%) 6/12(50%) 6/13(46%) 9/13(69%)  a - UPCI:SCC cell lines investigated: UPCI:SCC029B, SCC040, SCC056, SCC066, SCC078, 
SCC084, SCC099, SCC103, SCC104, SCC114, SCC116, SCC122, SCC125, SCC131, SCC136, 
SCC143, SCC172, SCC182. 
b- Weak positive correlation. 
c- Recurrence/relapse.  
d- Data extracted from (White, et al. 2007). 
e- Data extracted from (Telmer, et al. 2003; White, et al. 2007). 
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Figure 17. Kaplan-Meier survival analysis of CSLC (high) in 18 OSCC cell lines 
 
A. CD44 B. CD133/1 C. SOX2 D. BMI1. 
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3.2 DIVISION PATTERNS OF CSLC IN OSCC CELL LINES 
3.2.1 Division patterns of CSLC in OSCC cell lines 
To evaluate the division patterns of CSLC, we used IF staining, intensity mitotic pair analysis 
and size mitotic pair analysis utilizing a panel of CSLC markers (CD44, CD133/1, NESTIN, 
BMI1 and SOX2) in OSCC cell lines. Cluster analysis based on the intensity mitotic pair 
analysis was carried out (Figure 18); using a modification of the method described by Lathia et 
al. (Lathia, et al. 2011). Based on our cluster analysis results, symmetrical division was defined 
when the percentage difference of the stained marker is less than 20% and asymmetrical when 
the percentage difference is more than 20% (Figure 18). We found that only SOX2 showed 
significant equal and unequal distribution during mitosis as assessed by cluster analysis (Figure 
18). CD133/1 staining was faint, and was therefore not analyzed; CD44, NESTIN and BMI1 
showed some intensity variability (Figure 22); however the cluster and mitotic pair analysis (not 
shown) was not statistically significant.  
Under standard serum rich culture conditions, three distinct modes of cell division based 
on SOX2 were observed, Symmetric SOX2 self-renewing division (positive/positive pair), 
symmetric non-SOX2 differentiating division (negative/negative pair) and asymmetric SOX2 
self-renewing/differentiating division (positive/negative pair) (Figure 18). Analysis of the 
division patterns of SOX2+ mitotic pairs reveals that the main mode of division observed is 
symmetric division (≈ 75%), which leads to expansion of the CSLC population (Figure 18). 
Further assessment of the mitotic pair analysis based on SOX2 intensity shows that SOX2 begins 
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to be detected in early stages of cell division such as metaphase. In later stages of mitosis, SOX2 
is distinct in the mitotic pair (Figure 22). This might indicate that the specification of cell fate 
starts early in mitosis and gets determined all through the mitotic stages.  
We further assessed SOX2 staining during cell division by size mitotic pair analysis 
(Figures 18, 19). For this objective, we analyzed all the asymmetrical mitotic pairs based on size 
difference that we observed. As shown in Figure 19, some mitotic pairs (≈ 40%) showed size 
differences as well as intensity difference that we noted earlier. The sample mitotic pair shown in 
Figure 19 showed that one of the daughter cells (cell 2) was double the size of the other daughter 
cell (cell 1). Our size mitotic pair analysis adds further evidence supporting the presence of  
asymmetrical divisions in our cell lines. 
Furthermore, to confirm that the SOX2 mitotic division patterns we observed are not an 
artifact, dual IF staining with α-tubulin and phospho-Histone H3 was carried out (Figure 21). 
SOX2/α-tubulin dual staining confirmed that SOX2 determination exists in the dividing mitotic 
pair, during both symmetrical and asymmetrical cell division as evidenced by presence of 
cleavage furrows (Figure 22) (Lathia, et al. 2011). Similarly, phospho-Histone H3, a marker of 
mitotic division also showed equal symmetrical staining of the chromatin regardless of SOX2 
distribution (Figure 21). Overall, our results demonstrate that SOX2+ cells are capable of 
utilizing both symmetrical and asymmetrical cell division to maintain a SOX2+ population, this 
property being a characteristic of CSLC. 
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Figure 18. SOX2 as a marker of CSLC division  
 
A. SOX2 staining showing symmetrical and asymmetrical divisions of OSCC. B. Mitotic Pair 
analysis of the cell lines UPCI:SCC040 and UPCI:SCC131 using image analysis software 
(Image J). C. Cluster Plot of Mitotic Pair analysis of the cell lines UPCI:SCC040 and 
UPCI:SCC131 stained with SOX2 (n=63). Data were analyzed for statistical significance using 
the student’s t test. D. Percentage of symmetrical to asymmetrical divisions in OSCC cell lines 
UPCI:SCC040 and UPCI:SCC131. 
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Figure 19. Mitotic Pair analysis of a representative image from the cell line, UPCI:SCC131 
showing significant differences in cell size 
A. SOX2/DAPI stain merged B. SOX2 immunostaining C. Demarcated cell pair D. Artistic 
representative image of the size difference of the mitotic pair E. Histogram showing the size 
differences between the mitotic pairs F. Histogram showing the percentage of asymmetric 
mitotic pairs based on size difference. 
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Figure 20. Mitotic Pair analysis of representative images of the cell line UPCI:SCC131 in 
different stages of division 
 
In metaphase, SOX2 appears in the dividing cells; in anaphase, SOX2 immunostaining can be 
clearly identified in the mitotic pair. 
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Figure 21. Double immunofluorescence staining of SOX2+ CSLC with markers of 
cell division α-tubulin and phospho-Histone H3 
Double IF staining of SOX2+ CSLC with markers of cell division α-tubulin and phospho-
Histone H3 shows mitotic division and SOX2 redistribution during both symmetrical and 
asymmetrical division. 
 
 
 79 
 
Figure 22. Immunofluorescence staining of CSLC markers in OSCC cell lines during cell 
division 
IF staining with markers of CSLC, CD44, BMI1 and NESTIN shows symmetrical division and 
no asymmetrical division as confirmed by mitotic pair analysis. 
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3.2.2 Division patterns in response to IR and enriched spheroid medium  
To assess the possible changes in cell division patterns of SOX2+ CSLC in response to external 
environmental changes, we cultured OSCC cell lines on Matrigel™-coated plates and exposed 
the cells to IR regimens or enriched SC medium (Figure 23). We expected the dynamics of the 
division to change in response to the changes in the external environment owing to the central 
role of CSLC in disease progression. Our results show that the division pattern did not change in 
response to IR (2.5 Gy*3) and (2.5 Gy*6) as shown in Figure 23. On the other hand, when 
enriched medium was added to the culture, we observed a decrease in asymmetrical SC division 
(Figure 23). 
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Figure 23. SOX2+ CSLC division in response to IR and enriched SC medium 
 
A. Division patterns of SOX2+ CSLC in response to IR regimens; after three doses of 2.5 Gy 
and after six doses of 2.5 Gy. B. Division patterns of SOX2+ CSLC in response to enriched SC 
medium (Error bars +/- SEM). 
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3.2.3 Chromosomal Segregation Defects in CSLC in OSCC cell lines 
To assess CSD in CSLC and non-CLSC, we used SOX2 to mark CSLCs in OSCC cell lines in 
response 2.5 Gy IR (36 hrs post-IR). Assessment of CSD have been previously standardized in 
our lab; and based on our previous results, we chose UPCI:SCC040 and 131 for our study 
(Sankunny, et al. 2014; Saunders, et al. 2000). Based on our observation that SOX2 shows high 
correlation with other CSLC markers in dual-staining and that SOX2 was the only marker that 
showed symmetrical and asymmetrical division patterns, we choose SOX2 as a marker of CSLC. 
We then measured the frequencies of micronuclei, anaphase bridges, interphase chromosome 
bridges, and unclassifiable defects which are caused by misrepaired DNA and chromosomes 
and/or defective chromosomal segregation (Fenech, et al. 2011). 
The frequencies of CSDs in CSLC (SOX2+) and non-CSLC (SOX2-) are shown in 
Figures 23 and 24. Non-CSLC (SOX2-) had more than 20-fold higher frequency of CSDs when 
compared to CSLC (SOX2+). Interestingly, the segregation defects observed in CSLC were 
more frequently associated with symmetrical divisions than asymmetrical divisions (Figure 24). 
Furthermore, the types of segregation defects observed in CSLC (SOX2+) and non-CSLC 
(SOX2-) were different (Figures 24, 25). Anaphase bridges were predominant in CSLC (SOX2+) 
and micronuclei were predominant in non-CSLC (SOX2-). The difference in CSD between 
CSLC (SOX2+) and non-CSLC (SOX2-) might be due to some form of mitotic arrest by CSLC 
for repair of DNA defects or other causes. On the other hand, non-CSLC (SOX2-) seem to 
continue the cell cycle, resolving anaphase bridges into aberrant nuclear chromosomes, 
micronuclei, and/or interphase bridges. Overall, our results provide additional support to the 
proposition that CSLC have enhanced DNA repair machinery; further studies are warranted.  
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Figure 24. Chromosomal segregation defects in CSLC (SOX2+) CSLC and non-CSLC 
(SOX2-) 36 hrs after 2.5 Gy IR in OSCC cell lines (UPCI:SCC040 and 131)  
 
A. Percentage frequency of segregation defects in CSLC (SOX2+) and non-CSLC (SOX2-) (+/- 
SEM). 
B. Percentage frequency of segregation defects in symmetrical and asymmetrical CSLC 
(SOX2+) (+/- SEM). 
C. Types of segregation defects observed in CSLC (SOX2+) and non-CSLC (SOX2-) (+/- SEM). 
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Figure 25. Chromosomal segregation defects in CSLC (SOX2+) 36 hrs after 2.5 Gy IR 
 
Chromosomal segregation defects in CSLC SOX2+ (red) showing the main forms observed, 
including anaphase bridges, interphase bridges, and unclassifiable defects. Representative images 
of the defects are marked by arrows and the axis of division is indicated by a yellow line. 
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3.3 IMMUNOFISH OF CSLC IN OSCC CELL LINES 
To understand the role of copy number alterations and CIN in CSLC we did immune-FISH to 
compare CSLC (CD133+) and non-CSLC (CD133-) in OSCC cell lines, based on the marker 
CD133. Previous research has shown that CD133 is an important OSCC CSLC cell surface 
marker. Furthermore, our dual IF staining of CD133 with other CSLC markers showed high 
positive correlation. We used BAC FISH probe to enumerate ATM, since our group had 
previously shown that copy number loss of ATM is associated with radioresistance and enhanced 
response to combined therapy with IR and a CHEK1 SMI (Parikh, et al. 2007; Sankunny, et al. 
2014). Our results (Table 7; Figure 26) showed that the CSLC (CD133+) and non-CSLC 
(CD133-) expressed similar copy number loss or gain of ATM. Overall, our results suggest that 
loss of ATM can occur in CSLC. 
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Figure 26. Immuno-FISH results showing ATM copy number alterations in OSCC cell lines 
with and without distal 11q loss 
IF: CD133, FISH: Green: Cep11, Orange: ATM. CD133 Positive: A:UPCI:SCC29B, 
B:UPCI:SCC040; CD133 Negative: C:UPCI:SCC066, D:UPCI:SCC116. The results assessment 
is shown in Table 7. 
 
Table 7. Immuno-FISH results of UPCI:SCC cell lines* 
 
*IF: CD133/ FISH: ATM copy number status. The results show that the copy number alterations 
in cancer cells is similar to CSLC. 
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3.4 CHROMOSOMAL INSTABILITY IN CSLC FROM HNSCC AND OSCC CELL 
LINES 
We investigated the CSC stochastic model and CIN in CSLC derived from HNSCC CSLC cell 
cultures, kindly provided by Dr. Eric Lagasse. Copy number alterations in HNSCC#13 and 
clonally derived tumor clone HNSCC#13(E8) were assessed by six different centromeric FISH 
probes (experiments done by DL and analyzed by HK). Our results show that the HNSCC#13 
and HNSCC#13(E8) had chromosomal copy number alterations across all six chromosomes 
investigated (Figure 27). Our results thereby confirm that multiple copy number alterations 
developed in CSLC from the clone HNSCC#13(E8) CSLCs supporting the stochastic model of 
CSLC in HNSCC (Figure 27).    
In order to further investigate the possibility of a stochastic CSLC model, we generated 
clones from the cell line UPCI:SCC125, and then propagated these cloned cell lines (clones A, 
B, C and F6) in enriched SC media to investigate whether ATM copy number alterations are 
carried in the CSLC as suggested by the stochastic CSLC model (Table 8; Figure 28). All of the 
clones showed variation in ATM copy number, confirming that CSLCs express copy number 
alterations as proposed by the stochastic CSC model and as previously shown by Odoux et al. in 
metastatic colorectal cancers (Odoux, et al. 2008).  
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Figure 27. FISH analyses of CSLC isolated from HNSCC#13 and clone HNSCC#13 E8 
HNSCC#13 and HNSCC#13 (E8) CSLC cell lines showed variable number of chromosome 
copies across the six chromosomes assessed, supporting the stochastic model in HNSCC. 
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Table 8. FISH analysis of ATM copy number status in UPCI:SCC125 and derived clones 
 
 
Figure 28. FISH images of CSLC derived from UPCI:SCC125 and UPCI:SCC125 clones 
showing ATM copy number alterations 
FISH: Green: Cep11, Orange: ATM. UPCI:SCC125 cell line and UPCI:SCC125 cell line clones 
A, B, C and F6 show different ATM copy numbers in CSLC.     
Cell line/culture Percentage CSLC with loss of ATM  11q22.3 Percentage CSLC with no loss of ATM 11q22.3 
UPCI:SCC125 54 46
UPCI:SCC125 (Clone A) 12 88
UPCI:SCC125 (Clone B) 25 75
UPCI:SCC125 (Clone C) 10 90
UPCI:SCC125 (Clone F6) 91 9
HNSCC #13 5 95
HNSCC #13 (Clone E8) 60 40
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3.5 SPHEROID ENRICHMENT IN OSCC CELL LINES 
Most human epithelial cell lines with CSLCs can form spheroids in enriched suspension culture. 
In order to assess the CSLC potential in UPCI:SCC cell lines, we cultured these cells on ultra-
low attachment plates in SC-enriched media. All of our cell lines in the study formed spheroids 
(sphere–like or grape-like) in enriched suspension culture (Figure 29). The ability to form 
spheroids in vitro depends on the presence of self-renewing CSLCs within the population. To 
confirm the self-renewal potential of these cells, we tested a single cell suspension derived from 
primary spheroids for spheroid formation. There was a statistically significant difference 
between primary and secondary spheroids confirming our hypothesis (Figures 29, 30). 
Correlation analysis between CD133, CD44 and spheroid-forming capacity showed that CD133 
has a high correlation with spheroid forming capacity, unlike CD44 (Figure 31, 32). Further,  
suspension IF staining of the spheroids using stemness markers (CD44, CD133, SOX2 and 
BMI1) showed variable increases in positive (+++) cells expressing the marker especially in the 
spherical or grape-like structures; dispersed cell clusters were largely negative to the markers 
(Figure 33). Our results suggest that spheroid enrichment increases CLSC variably (Perego, et al. 
2011), confirming the heterogeneity of OSCC and the high likelihood of asymmetrical division 
in these cultures. To investigate the tumorigenic potential of single CSLCs from OSCC cell lines, 
we performed extreme limiting dilution assessment (ELDA) (Odoux, et al. 2008; Uchida, et al. 
2000). The ability to form colonies after extreme dilution is a unique and characteristic property 
of CSLC. Colony formation was observed ≈ 10 days after plating of OSCC cells in SC-enriched 
media. The estimation of spheroid forming efficiency (SFE) through extreme limiting dilution 
was 0.005-0.01% (Figure 34), which is similar to the results obtained by other groups using this 
experimental methodology (Odoux, et al. 2008; Tosoni, et al. 2012).  All cell lines studied 
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showed a statistically significant single hit hypothesis on stem cell analysis (Figure 34). To study 
the differentiation potential of CSLC, we transferred a single cell CSLC suspension derived from 
spheroids into Matrigel™-coated plates in serum-rich culture medium to test whether they could 
grow and differentiate into colonies (holoclones, paraclones and meroclones). Locke et al. 
previously described the clonal heterogeneity of OSCC cell lines as being ‘holoclones’ 
‘paraclone’ and  ‘meroclones’ (Locke, et al. 2005); we observed similar trends in our cell lines as 
described earlier (Locke, et al. 2005). All dissociated spheroids differentiated into colonies with 
specific characteristics (holoclones, paraclones and meroclones) with cells that demonstrated 
variability in cell size, shape and nuclear cytoplasmic ratio (Figure 35). Overall, the 
primary/secondary spheroid, ELDA, spheroid suspension IF staining and differentiation assay all 
confirmed that CSLC isolated from OSCC cell lines show properties of CSLC including self-
renewal, CSLC markers, colony forming capacity at extremely low dilutions, and differentiation 
potential in serum-rich media. 
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Figure 29. Phase contrast images of spheroids derived from UPCI:SCC cell lines 
 
Enriched spheroids showing sphere-like shape and grape-like shape in UPCI:SCC cell lines; A: 
UPCI:SCC029B; B: UPCI:SCC040; C: UPCISCC066; D: UPCI:SCC116; cell lines with distal 
11q loss (UPCI:SCC029B and 040) and cell lines without distal 11q loss cell lines 
(UPCI:SCC066 and 116). 
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Figure 30. Primary and secondary spheroid formation in UPCI:SCC cell lines  
 
UPCI:SCC029B, 040 and 066 showed a statistically significant increases in formation of 
secondary spheroids compared to primary spheroids (* p<0.05); UPCI:SCC116 showed an 
increase that was not statistically significant. 
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Figure 31. Correlation analysis between CD133 positive (+++) cells and spheroid formation 
showing a strong correlation 
 
 
 
 
Figure 32. Correlation analysis between CD44 positive (+++) cells and spheroid formation 
showing a weak correlation 
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Figure 33. IF staining of spheroids enriched from OSCC cell line UPCI:SCC029B 
showing positive cells in enriched spheroids and grape-like colonies  
 
IF suspension staining of the spheroids using stemness markers (CD44, CD133, SOX2 and 
BMI1) showed variable increases in positive (+++) cells expressing the marker especially in the 
spherical or grape-like structures; dispersed cell clusters were largely negative for the markers. 
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Figure 34. Stem cell frequency assessment by extreme limiting dilution analysis  
A. Goodness of fit tests. Rejection of the tests may be due either to batch effects 
(heterogeneity in the stem cell frequencies or assay success rate) or to a failure of the 
stem cell hypothesis. Single hit likelihood ratio was statistically significant, p<0.05 in all 
UPCI:SCC cell lines; likelihood ratio based on goodness of fit plot in UPCI:SCC040 and 
UPCI:SCC131 is represented. 
B. Limiting Dilution plate setup: 2000 cells/well were serially diluted to 8 cells/well. 
C. Stem Cell Frequency was estimated by extreme limiting dilution assessment utilizing SC 
analysis software (Hu and Smyth 2009) in cell lines with distal 11q loss 
(UPCI:SCC029B, 040 and 131) and  without distal 11q loss (UPCI:SCC066 and 116). 
The values represent the estimation of CSLC frequency with upper limit (UL) and lower 
limit (LL) values setting a range. No statistically significant difference was observed 
between the two groups. 
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Figure 35. Differentiation assay of OSCC CSLC 
 
CSLC enriched as spheroid (non-adherent) can differentiate into heterogeneous colonies which 
are comprised of cells that vary in shape and size when cultured in serum-rich media. 
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3.6 CSLC RADIORESISTANCE PATTERNS IN OSCC 
3.6.1 Role of distal 11q loss in CSLC radioresistance  
The response of OSCC CSLC cells to IR was assessed by spheroid survival assay, cell viability 
assay, ELDA and growth assay. The response of parental OSCC was previously studied 
previously in our lab and was confirmed by clonogenic survival assays (Parikh, et al. 2007). The 
cell lines were divided into two groups: ‘Distal 11q loss’ and ‘No distal 11q loss.’ Cells were 
treated with IR doses of 2.5 Gy and 5 Gy, based on previous studies in our lab (Parikh, et al. 
2007; Sankunny, et al. 2014). Results were reported as ‘Surviving Fraction’ for each IR dose 
after normalization against untreated cells (UT). The clonogenic survival assays of the parental 
cell lines showed similar trends to that previously reported by our lab, with the ‘Distal 11q loss’ 
group (UPCI:SCC029B and 040) showing radioresistance compared to the ‘No distal 11q loss’ 
group (UPCI:SCC066 and 116) (Figures 38, 39) (Parikh, et al. 2007; Sankunny, et al. 2014). 
Interestingly, spheroid survival assays of the two groups, ‘Distal 11q loss’ and ‘No distal 11q 
loss’ also showed a similar overall trend (Figures 35, 36). However, we observed marked 
radioresistance and a SF above 50% in spheroids regardless of IR dose or 11q copy number 
status. The overall trends in the spheroid survival assay were confirmed by cell viability assays; 
CSLC with distal 11q loss showed greater radioresistance compared to cells without distal 11q 
loss (Figure 40). We assessed the SFE by ELDA in response to IR; neither group showed a 
statistically significant reduction in CSLC (Table 9). Furthermore, we assessed spheroid growth 
on agarose-coated plates utilizing a low cell seeding density approach (Figures 41-44). No 
statistically significant reduction in spheroid size was observed in response to IR in either group 
(distal 11q loss/no distal 11q loss). Overall, our results confirm that CSLC are radioresistant 
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through all the approaches (Figures 36-44). Distal 11q loss was associated with radioresistance in 
CSLC as shown by both the spheroid survival assay and cell viability assay (Figure 36-40). No 
statistical significance was observed in the SFE as examined by ELDA and spheroid growth 
assay (Table 9; Figure 41-44). Overall, our results may suggest a role for distal 11q loss in 
OSCC CSLC. Further investigation of this possibility is warranted in a larger sample of cell 
lines. 
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Table 9. Stem cell frequency assessment by ELDA in OSCC cell lines in response to IR* 
 
 
 
* Stem cell frequency was estimated by extreme limiting dilution assessment utilizing SC 
analysis software (Hu and Smyth 2009). 
*The values represent the estimation of SC frequency with upper limit (UL) and lower limit (LL) 
values setting a range. 
* UPCI:SCC040, 131 and 066 showed no significant statistical reduction in CSLC frequency in 
in response to IR; UPCI:SCC116 showed a statistically significant reduction in CSLC frequency 
that is probably not biologically significant.  
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Figure 36. Spheroid survival assay in UPCI:SCC cell lines after treatment with IR 
 
The surviving fraction of spheroids at speciﬁc IR doses is higher in the “Distal 11q loss” group 
(UPCI:SCC029B and 040) when compared to the “No distal 11q loss” group (UPCI:SCC066 and 
116). Statistical assessment is shown in Figure 37. 
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Figure 37. Spheroid survival Assay in UPCI:SCC cell lines 
 
The surviving fraction of spheroids at speciﬁc IR doses is plotted with error bars (+/-SEM). 
Spheroids in the “distal 11q loss” group (UPCI:SCC029B and 040) showed increased survival 
compared to the “no distal 11q loss” group (UPCI:SCC066 and 116). 
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Figure 38. Clonogenic survival of UPCI:SCC cell lines after treatment with IR 
 
The surviving fraction of cells at speciﬁc IR doses is higher in the “distal 11q loss” group 
(UPCI:SCC029B and 040) when compared to the “no distal 11q loss” group (UPCI:SCC066 and 
116). Statistical assessment is shown in Figure 39. 
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Figure 39. Clonogenic survival assay in parental OSCC cell lines 
 
The surviving fraction of cells at speciﬁc IR doses is plotted with error bars (+/-SEM) on a 
logarithmic scale. Cancer cells in the “Distal 11q loss” group (UPCI:SCC029B and 040) showed 
increased survival when compared to the “No distal 11q loss” group (UPCI:SCC066 and 116). 
 
 105 
 
 
Figure 40. Assessment of CSLC survival in cells with and without distal 11q loss grown on 
matrigel-coated plates 
 
A. Cell viability assay; red refers to dead cells and green refers to live cells.   
B. CSLCs in the “distal 11q loss” group (UPCI:SCC029B and 040) showed increased survival 
compared to the “no distal 11q loss” group (UPCI:SCC066 and 116)(* p<0.05). 
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Figure 41. Spheroid growth assay in OSCC cell lines with distal 11q loss 
Spheroid growth assessment was done by culturing OSCC cells in agarose-coated 96-well plates, 
utilizing a low cell seeding density approach. Spheroids >65µm were marked, counted and 
analyzed for size growth using image analysis software (Image J). Statistical assessment is 
shown in Figures 43 and 44.  
 
Figure 42. Spheroid growth assay in OSCC cell lines without distal 11q loss  
Spheroid growth assessment was done by culturing OSCC cells in agarose-coated 96-well plates, 
utilizing a low cell seeding density approach. Spheroids >65µm were marked, counted and 
analyzed for size growth using image analysis software (Image J). Statistical assessment is 
shown in Figures 43 and 44. 
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Figure 43. Assessment of spheroid growth assay in OSCC cell lines 
Spheroid size (growth) assessment in cell lines with ‘Distal 11q loss’ (UPCI:SCC029B and 040) 
when compared to cell lines with “No distal 11q loss” (UPCI:SCC066 and 116).  
 
 
Figure 44. Assessment of spheroid growth in OSCC cell lines with distal 11q loss and 
without distal 11q loss  
Spheroid size (growth) assessment in cell lines with ‘Distal 11q loss’ (UPCI:SCC029B and 040) 
when compared to cell lines from the “No distal 11q loss” group (UPCI:SCC066 and 116). No 
statistically significant difference was observed between the two groups. 
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3.6.2 Role of CSLC in radioresistance  
In an effort to replicate the clinical therapeutic scenario (Lagadec, et al. 2010), in which patients 
receive multiple doses of IR (2.5 Gy) daily over a period of weeks, we irradiated CSLC with 2.5 
Gy every other day for 1 or 2 weeks respectively. The surviving fraction of spheroids at different 
total IR doses showed no statistical significance at 2.5 Gy*1, 2.5 Gy*3 and 2.5 Gy*6, confirming 
the possible contributory role of CSLC to radioresistance (Figure 45).  
Next, we assessed the spheroid migration zone, a standardized approach used to measure 
the short-term therapeutic response of CSLC; the approach also mimics the initiation of 
metastases or recurrence that occurs in vivo (Vinci, et al. 2013).  The enriched spheroids from the 
‘No distal 11q loss’ cell lines (UPCI:SCC066 and 116) did not migrate on matrigel or poly-L-
lysine coated plates. On the other hand, the ‘Distal 11q loss’ cells (UPCI:SCC040 and 131) 
formed a migration zone on matrigel-coated plates. The assay showed mild reduction in the 
spheroid migration zone in response to IR in UPCI:SCC131 and no significant reduction in 
spheroid migration area in UPCI:SCC040, confirming the role of CSLC in radioresistance 
(Figure 46). Overall, the trends that we observed in the migration assays (Figure 46) were similar 
to the trends that we observed in the long-term therapeutic response experiments (spheroid 
survival assay, cell viability assay, ELDA, spheroid growth assay) (Figures 36, 37, 40-44; Table 
9).  
In order to assess the response of the DDR machinery in CSLC post-IR, CSLC were 
cultured on matrigel™-coated plates in enriched SC media. Various DDR components (γH2AX, 
pCHEK1 and KU70) showed a statistically significant increase in foci after IR (Figure 47), 
confirming the role of DDR in CSLC response to IR 2.5 Gy. Overall, our results confirm that 
CSLC are an important factor in radioresistance of OSCC. 
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Figure 45. Spheroid survival assay in OSCC cell lines after treatment with IR regimens 
 
The surviving fraction of spheroids (UPCI:SCC0040 and 131) at different total doses of IR 
shows no statistical significance across regimens.   
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Figure 46. Quantification of spheroid-based migration in response to IR 
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A. Line graphs showing quantification of UPCI:SCC040 and 131 cell migration on Matrigel™-
coated plates at 96 hr in response to IR (mean ± SEM of replicate spheroids). Migration was 
assessed at 96 hr relative to original spheroid size at (t=0) for each condition. The area of the 
spheroids (S) at t = 0 and the area covered by the cells that have migrated from the spheroids (M) 
was determined after 4 days. Data were normalized to the original spheroid recorded using the 
following formula: % migration zone=migrated area (M)(t= 96 hr) /original spheroid (S) (t = 0) × 
100. 
B. Images showing spheroid-based migration in response to IR (stained with Giemsa stain). 
C. Analyzed images showing spheroid-based migration marked as M (Migration Zone) and 
original Spheroid at (t=0) S (Spheroid Zone).   
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Figure 47. DNA damage response in cancer stem-like cells enriched from UPCI:SCC cell 
lines in response to IR 
A. γH2AX foci in cancer stem-like cells, untreated and 1 hr post-IR (mean ± SEM). 
B. KU70 foci in cancer stem-like cells, untreated and 1 hr post-IR (mean ± SEM). 
C. pCHEK1 foci in cancer stem-like cells, untreated and 1 hr post-IR (mean ± SEM). 
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3.7 COMBINED IR AND CHEK1 INHIBITION OF CSLC IN OSCC 
Our group and others have shown previously that a CHEK1 SMI can radiosensitize cancer cells 
to IR (Blasina, et al. 2008; Sankunny, et al. 2014). We tested the response of CSLC to combined 
therapy with IR and CHEK1, by the following measures: spheroid survival assay, cell viability 
assay, ELDA and spheroid migration assay. CSLC were treated with CHEK1 for 48 hr (8 hr 
before-radiation treatment) based on our previous findings (Sankunny, et al. 2014). The 
combination of IR and CHEK1 SMI reduced the survival of CSLC compared to a single IR 
treatment (Figures 48-50). The spheroid survival assay showed no statistical significance 
between CSLC with and without distal 11q loss across all combinations assessed (2.5 Gy/100 
nM, 2.5 Gy/1 µM and 2.5 Gy/10 µM) (Figure 48). Only 2.5 Gy/10 µM was potent in eradicating 
CSLC in either group. On the other hand, ELDA showed that the combination 2.5 Gy/1 µM was 
statistically significant when compared to 2.5 Gy/0 nM; however, only the combination 2.5 
Gy/10 µM inhibited stem cell frequency effectively to less than 1/1000 in both groups (Table 
10). Again, our results in Table 10 showed no statistically significant difference in SC frequency 
in response to the therapeutic combination based on distal 11q loss (Distal 11q loss group: 
UPCI:SCC040 and 131; No distal 11q loss group:UPCI:SCC066 and 116). Our results of a cell 
viability assay demonstrated that only the combination of 2.5 Gy/10 µM could possibly inhibit 
CSLC to less than 20% (Figure 49). Our results also showed no statistically significant 
difference between the two groups based on distal 11q loss (Figure 49). The spheroid migration 
assay was done only on CSLC derived from distal 11q loss spheroids (UPCI:SCC040 and 131) 
because spheroids derived from CSLC without distal 11q loss (UPCI:SCC066 and 116) did not 
migrate on Matrigel™-coated plates. The results confirmed that only the combination of 2.5 
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Gy/1 µM could partially inhibit spheroid migration. The 2.5 Gy/10 µM combination effectively 
inhibited spheroid migration completely in both cell lines. 
Overall, the spheroid survival assay, cell viability assay and spheroid migration assay 
showed that a high CHEK1 inhibitor dose, as high as 100-fold the dose effective on parental cell 
lines was required to effectively inhibit CSLC (Figures 47, 48; Table 10). Effective CHEK1 
inhibitor doses of ≈300-500 nM/dl were effective in inhibiting cancer cells in vitro (Blasina, et 
al. 2008; Sankunny, et al. 2014), while only doses ≈1-10 µM/dl were effective in CSLC (Figures 
48-50; Table 10). The response to the IR/CHEK1 combination was not ‘Distal 11q loss’ driven, 
suggesting that CSLC possess a complex DDR therapeutic resistance machinery that differs from 
that in non-CSLC. 
 
Figure 48. Spheroid survival in CSLC with and without distal 11q loss in response to 
combined IR and CHEK1 SMI (+/- SEM) 
The results show no statistical significance between the two groups in response to different 
IR/CHEK1 combinations. Distal 11q loss (UPCI:SCC029B and UPCI:SCC040), No distal 11q 
loss (UPCI:SCC066 and UPCI:SCC116). 
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Table 10. Stem cell frequency in OSCC cell lines, assessed by ELDA in response to 
combined IR and SMI CHEK1*  
 
 
* Stem cell frequency was estimated by extreme limiting dilution assessment utilizing SC 
analysis software (Hu and Smyth 2009). 
*The values represent the estimation of SC frequency with upper limit (UL) and lower limit (LL) 
values setting a range limit. 
*Only the combination 2.5 Gy/10 µM inhibited stem cell frequency effectively to less than 
1/1000 in both groups. 
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Figure 49. Cell viability in response to combined IR and CHEK1 SMI inhibitor  
(PF-0077736), comparing various doses of SMI 
 
Line graphs showing response of A. UPCI:SCC040, B. UPCI:SCC066, C. UPCI:SCC116 and D. 
UPCI:SCC131 CSLC to IR/CHEK1 inhibitor combination (0 Gy/0 nM, 2.5 Gy/100nM, 2.5 Gy/1 
μM and 2.5 Gy/10μM). Distal 11q loss cell lines (UPCI:SCC040 and 131) and no distal 11q loss 
cell lines (UPCI:SCC066 and 116 ). No statistical significance was observed between the two 
groups. 
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Figure 50. Quantification of spheroid migration in response to combined IR2.5 and 
CHEK1 small molecule inhibitor 
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A. Line graphs showing quantification of UPCI:SCC040 and 131 cell migration on Matrigel™-
coated plates at 96 hr in response to combined IR and CHEK1 small molecule inhibitor (mean ± 
SEM of replicate spheroids). Migration was assessed at 96 hr relative to original spheroid size at 
(t=0) for each condition. The area of the spheroids (S) at t = 0 and the area covered by the cells 
that have migrated from the spheroids (M) was determined after 4 days. Data were normalized to 
the original spheroid recorded using the following formula: % migration zone=migrated area 
(M)(t= 96 hr) /original spheroid (S) (t = 0) × 100. 
B Images showing spheroid-based migration in response to combined IR and CHEK1 small 
molecule inhibitor (2.5 Gy/100 nM and 2.5 Gy/1 μM) (stained with Giemsa stain). 
C. Analyzed images showing spheroid-based migration marked as M (Migration Zone) and 
original Spheroid at (t=0) S (Spheroid Zone).   
 
 119 
4.0  DISCUSSION  
4.1 CSLC MARKERS IN OSCC CELL LINES 
One of the characteristics of CSLC is the presence of unique cell surface markers. Breast cancer 
was the first solid tumor in which CSLC were isolated, as a result of the expression of a high 
level of CD44 and a low level of CD24 cell surface markers (Al-Hajj, et al. 2003). Identifying 
CSLC using cell surface markers aids in quantifying these cells in tumors. We used low cell line 
passages that resemble to a large extent the primary tumors (Wilson, et al. 2012). We 
investigated by IF the frequency of four markers CD44, CD133, SOX2 and BMI1 a panel of 18 
UPCI:SCC cell lines (Table 6). Based on analysis of our results, we observed that OSCC can be 
classified based on intensity of staining into three major categories (+/++/+++); CD133 and 
CD133/1 were the only markers expressed as (+/-). OSCC cells with positive (+++) were 
categorized as CSLC based on the correlative evidence we observed on double IF staining as 
well as previous research (Harper, et al. 2007; Li, et al. 2014; Locke, et al. 2005). 
Our IF and flow cytometry results showed that CD44 is not be a suitable marker for 
identifying CSLC in OSCC. The average frequency of CD44-positive (+++) cells in 18 OSCC 
cell lines was 23% (Table 5), which is higher than expected compared to the findings of other 
research groups testing CSLC markers (Clay, et al. 2010; Zhang, et al. 2010). Further, the flow 
cytometry results confirmed that CD44 is constitutively expressed in three of four cell lines that 
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we assessed, making flow sorting for CSLC using this marker less useful. On IF, only rare cells 
did not express CD44, so we did not include a non-expressing category. Our average CD44-
positive frequency seems to concur with results obtained by Joshua et al., who found an average 
of 25% CD44-positive cell in a panel of 31 HNSCC primary tumors (Joshua, et al. 2012). 
Double IF staining with other stemness markers, including SOX2, BMI1 and NESTIN confirmed 
that the majority of CD44-positive cells did not double-stain with other stemness markers, 
adding further evidence to our conclusion that CD44 is not a sensitive CSLC marker (Figures 14, 
15). Furthermore, IF staining of the control cell line, OKF6, showed the CD44-positive cells at ≈ 
5%, confirming that CD44 is not cancer-specific (Figures 12, 13). Research has shown that 
CD44 and variant CD44 isoforms are expressed in both normal and cancerous oral tissue (Mack 
and Gires 2008). The expression of CD44 in normal oral cells as well as CSLC therefore 
necessitates the addition of another specific CSLC marker. Overall, our results concur with other 
papers that concluded that CD44 might not be a suitable marker for CSLC in OSCC or HNSCC 
(Chen, et al. 2012; Shrivastava, et al. 2015). 
CD133 and CD133/1, on the other hand, are more promising cell surface markers of 
CSLC in OSCC cell lines. The mean frequency of CD133-positive cells was ≈ 6%, which is 
concordant with being a small subpopulation in the tumor according to the hierarchic CSLC 
model. CD133 was highly correlated with other stemness markers on double IF and correlated 
highly with spheroid-forming capacity when assayed in a series of cell lines (Figures 14, 15). 
Overall, our results concur with other papers that concluded that CD133 and CD133/1 is a 
suitable markers for CSLC in OSCC (Chen, et al. 2012; Shrivastava, et al. 2015). CD133 
(Abcam) was consistent, clear and robust across cultures, unlike CD133/1 (Miltenyi). Problems 
of CD133/1 as a possible cell surface marker in OSCC include faint/dim staining and 
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inconsistency across cultures (Figure 8). Furthermore, we concur that the dimness of CD133/1 
makes the flow cytometric analysis of the population difficult (Harper, et al. 2007). 
Inconsistency of CD133/1 IF staining across cultures has been reported previously in colorectal 
CSLC (Dalerba, et al. 2007; Odoux, et al. 2008). Possible explanations for the CD133/1 
inconsistency include the inter-observer bias because of the difficulty of assessing dim/faint sub-
populations in IF/flow cytometry and manufacturing properties related to the CD133/1 antibody 
itself. The antibody as produced by the company has a very limited stability (6 months) and is 
prepared in an extremely diluted form that requires an extremely unusual low dilution of ≈1/10. 
These observations were discussed with the manufacturing company (Miltenyi, Inc.) and we 
were one of the labs that tested their new, improved CD133/1 conjugated with viobright-FITC. 
Unfortunately, the new product was as dim/faint as the earlier product. Overall, technical 
difficulties related to CD133/1 staining in OSCC are clear and have been observed previously by 
others (Locke, et al. 2005).  
CSLC markers in primary tumors and cell lines may not truly reflect all of the biological 
features of CSLC, primarily due to loss of the niche interaction that plays an important role in 
regulating many properties of CSLC, including cell division pattern and rate. In addition, culture 
adaptation and genetic alterations taking place during long-term culture under hypoxic culture 
conditions may lead to overestimation of the frequency of CSLC markers in cell lines (Wang, et 
al. 2013). In spite of this, some research groups observed consistent CSLC markers between 
early and late passages (Bunger, et al. 2012; Harper, et al. 2007; Locke, et al. 2005). Further 
research on CSLC identification markers seems crucial to enable researchers to further study this 
subpopulation.  
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Our results show that the ability to form large spheroids (>100 μm) does not correlate 
with the percentage of CSLC detected either by single or double marker staining. This concurs 
with CSLC analysis of primary breast tumors (Grimshaw, et al. 2008). CD133-positive cells 
highly correlated with spheroid-forming capacity in a group of OSCC cell lines that we assessed 
(Figure 31); however, increasing the sample size to verify our results is warranted. In conclusion, 
currently there is no consensus regarding the most suitable cell surface markers for the 
identification of CSLCs in OSCC. Our results show that double immunostaining is the most 
effective approach in analyzing the CSLC population in OSCC cell lines and possibly, primary 
tumors. 
4.2 PROGNOSTIC SIGNIFICANCE OF CSLC IN OSCC CELL LINES 
The identification of biomarkers in OSCC that predict the potential of recurrence or progression 
in patients will aid in selecting patients who could benefit the most from adjuvant treatments. We 
did not find prognostic significance between CSLC markers and various parameter of disease 
(Table 6). We expected the results to some extent because OSCC is a complex heterogeneous 
cancer driven by multiple genetic and environmental factors. In addition, the functional 
assessment of CSLC potential using extreme limiting dilution showed similar tumor initiating 
potential (<0.1%), suggesting that CSLC frequency is not the main force driving disease 
progression (Figure 34). Furthermore, double IF staining with CSLC markers showed that our 
cell lines had similar frequencies of CSLC-positive cells (1-3%) when double stained with  
CSLC markers (Figures 14, 15). These results suggest that not all cells with CSLC markers 
possess tumor initiating potential. Furthermore, non-CSLC cells, such as CD44-negative cells, 
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have been shown to be tumorigenic in HNSCC and other cancers, suggesting that single CSLC 
markers are insufficiently sensitive enough to assess CSLC in tumors (Oh, et al. 2013; Wang, et 
al. 2008). Our results strongly suggest that the CSLC subpopulation is dynamic and can be 
influenced by stochastic factors, such as IR and tumor re-initiation modeled by culture cloning as 
suggested by Lagasse (Lagadec, et al. 2010; Lagasse 2008; Odoux, et al. 2008). 
A longitudinal clinical study in a large population to assess the prognostic value of CSLC 
in OSCC is necessary to validate our results. However, the inconsistencies in the prognostic 
value of CSLC markers in OSCC are clear when reviewing the literature (Table 2), and extend 
across other tumors, such as hepatocellular carcinoma (Salnikov, et al. 2009). The lack of tumor 
specificity of CSLC markers, such as CD44 further adds complexity to the assessment of CSLC 
frequency in tumors. Overall, based on our current results and a review of the current literature 
we believe that the tumorigenicity of CSLC will likely be closely linked to multiple factors that 
include HPV status (Zheng and Franzmann 2013), the mutational status of driver genes, as well 
as the copy number status within the tumor (Gollin 2014).   
4.3 DIVISION PATTERNS OF CSLC IN OSCC CELL LINES 
Division utilizing both symmetrical and asymmetrical cell division is an important characteristic 
of SC. The facultative use of symmetric or asymmetric divisions by SCs is a key adaptation 
crucial for both development and regeneration (Morrison and Kimble 2006). Asymmetric cell 
division is important in growth and development of many invertebrates such as Drosophila 
melanogaster and Caenorhabditis elegans (Knoblich 2010). Cell division fate is regulated by 
intrinsic and extrinsic mechanisms. Intrinsic mechanism are regulated by the partitioning of cell 
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components that determine cell fate such as cell polarity and segregation determinants; while 
extrinsic mechanisms are regulated by signaling from the external environment (Morrison and 
Kimble 2006). In Drosophila melanogaster, asymmetric cell division is mediated by the protein 
Numb that inhibits Notch–Delta signaling; this is followed by asymmetric localization of adaptor 
proteins, such as Brat (Knoblich 2010). Asymmetrical division is tightly regulated during 
interphase through telophase (Knoblich 2010; Morrison and Kimble 2006). Par proteins mediate 
spindle orientation; in asymmetric cell division, cell fate determinants are inherited by only one 
of the two daughter cells (Betschinger and Knoblich 2004; Knoblich 2001; Knoblich 2010; 
Wang, et al. 2007). Functional differences in cellular properties as well as differences in cell size 
have been noted in invertebrates immediately post-mitosis (Knoblich 2010). In mammalian cells, 
the critical role of NUMB was confirmed in both mouse and human cells and has been critical to 
our understanding of the process of asymmetrical division. NUMB was found to localize to one 
edge of a daughter cell, forming a crescent-shaped pattern that segregates into only one of the 
two daughter cells. NUMB mediates NOTCH signaling, that in turn regulates PROX1, a 
transcription factor and BRAT, a regulator of post-transcriptional events (Knoblich 2010). 
In some adult SCs, such as hematopoietic SC, asymmetrical division is the main form of 
division employed to maintain tissue homeostasis. However, in the case of injury or disease, 
switching to symmetrical division is possible (Morrison and Kimble 2006). Similarly, SCs in 
mammalian epithelial tissues require asymmetrical division and axis polarity to generate 
specialized differentiated cell progeny, while ensuring SC equilibrium (Clevers 2005). The 
interconnection between SCs, asymmetric cell division and carcinogenesis has been an active 
area of research for more than a decade. The hallmark study by Caussinus and Gonzalez in 
Drosophila, showed that tumor formation is associated with the switch of SC division machinery 
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from asymmetrical to symmetrical (Caussinus and Gonzalez 2005). Functional studies by 
Caussinus and Gonzalez showed that defective asymmetrical division of neuroblast SC was 
associated with marked cellular hyperplasia as well as generation of satellite tumors distant from 
the site of injection; further, sequential transplantation was also associated with tumor initiation 
and the emergence of genomic instability in cells (Caussinus and Gonzalez 2005). In mammalian 
SC, asymmetric cell divisions are correlated with tumor suppression (Humbert, et al. 2003). 
Functional studies in breast cancer cells demonstrated that loss of NUMB may be associated with 
the hyperactivation of NOTCH pathway signaling that leads to an increase in symmetrical 
division (Pece, et al. 2004). Symmetrical cell division also seems to promote genetic instability, 
an important characteristic of solid tumors (Gollin 2005; Hanahan and Weinberg 2000; Hanahan 
and Weinberg 2011; Morrison and Kimble 2006; Reshmi, et al. 2004). Research has shown that 
asymmetrical cell division is a more tightly regulated process because of the need to change the 
fate of one of the daughter cells; therefore symmetric divisions might not only increase CSLC 
numbers, but also increase the probability of genetic instability and other secondary mutations by 
disrupting the controls on centrosomes and mitotic spindles (Caussinus and Gonzalez 2005; 
Morrison and Kimble 2006). 
Understanding the regulation of asymmetric cell division in CSLCs will provide insight 
into tumor initiation, growth, and maintenance (Pine, et al. 2010). One of the key questions in 
CSLC biology concerns the mechanisms that regulate division patterns of CSLC, and thereby 
tightly regulate the self-renewal/differentiation balance within the tumor. Different epigenetic 
profiles have been suggested as one of the mechanisms that might regulate cell fate (Lansdorp 
2007). Improvements in immunostaining, cell culturing and imaging technology, such as time 
lapse imaging have given researchers new tools to study cell division in CSLC. In the field of 
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CSLC, there remains a need to assess which molecules can segregate asymmetrically in order to 
identify this type of division.  
Recently, Tomasetti and Vogelstein proposed a theory based on the cancer stem cell 
(CSC) stochastic model (Tomasetti and Vogelstein 2015). They proposed that differences in 
organ-specific cancer risk is largely due to mutation in non-CSC. Based on Tomasetti and 
Vogelstein’s mathematical modelling, the stochastic origin of CSC might be a bigger contributor 
to cancer than hereditary and environmental factors. They based their assumption on the fact that 
most human cells have similar mutation rates, but different proliferative rates; a functional 
property regulated by SCs within each organ. Correlation analysis of SC division and cancer life 
time risk across 31 different tumors was highly significant (0.804; p<0.05) (Tomasetti and 
Vogelstein 2015). 
Research has shown that CSLC are present in cell lines and that they can be isolated and 
propagated for a number of passages on laminin or other ECM proteins, such as Matrigel™ (Sun, 
et al. 2008). The frequency of asymmetric division of BrdU-labeled template DNA in NSCLC 
was ≈ 5% (Pine, et al. 2010), similar to the asymmetrical division ratio in murine muscle satellite 
cells in vitro (Shinin, et al. 2006). Pine et al. showed that environmental factors, such as 
increased cell density, hypoxia and serum deprivation decreases asymmetrical division in CSLC 
(Pine, et al. 2010). Lathia et al. demonstrated using CD133 and time-lapse imaging that CSLC in 
glioma divided both symmetrically and asymmetrically (70%:30%). They observed that only 
CD133, and no other CSLC markers are distributed both symmetrically and asymmetrically. 
Further, they observed that symmetrical division increases with the introduction of enriched 
CSLC culture medium (Lathia, et al. 2011). Liu et al. showed that asymmetrical division in 
breast CSLC correlates with increased invasion and migration (Liu, et al. 2013). This is possibly 
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because non-CSLCs possess a higher proliferative capacity. Further, they showed that division 
patterns of CSLC might be affected by the CSLC niche, such as the presence of mesenchymal 
cells (Liu, et al. 2013). Izumi and Kaneko found that cell division might be regulated by driver 
oncogenes, such as MYCN in neuroblostoma cell lines; MYCN overexpression being associated 
with symmetrical division (Izumi and Kaneko 2012). The pioneering work of Izumi and Kaneko 
might be of significant value if similar results are observed in other cancers. Overall, it is clear 
that CSLC division is an interesting new area of research with topics such as the implications of 
the type of division on mutation accumulation still remains unclear (Shahriyari and Komarova 
2013).  
Our group has shown previously that cancer cells in OSCC cell lines show abnormal cell 
division patterns, dysfunctional cytokinesis, and segregation defects (Sankunny, et al. 2014; 
Saunders, et al. 2000). We studied the division patterns in two of our cell lines (UPCI:SCC040 
and 131) using CSLC markers (CD44, CD133, SOX2 and BMI1). SOX2 was the only marker 
that showed statistically significant symmetrical and asymmetrical division patterns; analysis of 
other CSLC markers only showed symmetrical division. Sex-determining region Y [SRY]-box 
(SOX2) is a SC transcription factor that was originally demonstrated in embryonic SC (ESC) and 
was found to mediate self-renewal and pluripotency of SC (Okumura-Nakanishi, et al. 2005; 
Sarkar and Hochedlinger 2013). In addition, SOX2 is one of the key transcription factors capable 
of reprogramming differentiated somatic cells into induced pluripotent stem (iPS) cells 
(Takahashi, et al. 2007; Yu, et al. 2007). Later, another research group identified SOX2 in adult 
tissue SC, including squamous epithelium of the tongue (Okubo, et al. 2009).  Recently, SOX2 
has also been found to be a functional marker of CSLC in various tumors, including HNSCC 
(Lee, et al. 2014). Silencing of SOX2 in vitro has been shown to decrease CSLC self-renewal, 
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chemoresistance, invasion capacity, and in vivo tumorigenicity (Lee, et al. 2014). SOX2 
overexpression in HNSCC was found to lead to cyclin B1 and SNAI1 overexpression, as 
probable mechanisms that might give these cells a survival advantage (Lee, et al. 2014). A 
possible role for SOX2 as an independent CSLC marker in HNSCC has also been suggested by 
multiple studies (Table 2). Overall, the role of SOX2 in CSLC has been confirmed in multiple 
studies of different tumors.  
Our OSCC division results are similar to that observed in other tumors such as 
neuroblastoma and glioblastomas (Beckmann, et al. 2007; Izumi and Kaneko 2012; Lathia, et al. 
2011) and other SC such as hematopoietic SCs (Beckmann, et al. 2007). Our results establish the 
UPCI:SCC cell lines as useful experimental preclinical models for further assessment of the 
biology of CSLC cell division and for testing possible therapeutic strategies that target the 
stemness pathway. 
Analysis of our results showed that the division pattern did not change based on IR 
treatment strategies, suggesting that cell division patterns of CSLC might be difficult to 
manipulate utilizing standard therapeutic approaches. The high prevalence of symmetrical 
division, even after IR treatment, might be explained by the enhanced radioresistance of CSLC 
compared to differentiated progeny, a robust mechanism which can thereby maintain tissue 
homeostasis even in unfavorable conditions (Shahriyari and Komarova 2013). Further, CSLC 
had fewer segregation defects when compared to non-CSLC. The decreased segregation defects 
in addition to the predominance of symmetrical division protect CSLCs from IR-induced DNA 
damage. Understanding CSLC biology and division is essential before effective targeting of this 
subpopulation can be implemented. Unanswered questions in CSLC biology include how the 
type/rate of cell division contributes to SC regulation, how SC switch between the two modes of 
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division, and how cancer changes SC division (Shahriyari and Komarova 2013). Previous studies 
showed that human OSCC contain CSLC with a distinct phenotype, including features of self-
renewal, induction of multi-lineage cell differentiation, and high drug efflux capacity (Harper, et 
al. 2007; Lim, et al. 2011; Liu, et al. 2012). Our present findings add the asymmetrical division 
phenotype to the features of OSCC CSLC. We showed in our current work that it is possible to 
analyze asymmetric cell division in cultured OSCC cells. Division patterns in OSCC that we 
observed are mainly related to the intrinsic cellular machinery and not dependent on cell-to-cell 
contact or a stem cell niche. Changes in cell microenvironment, such as CSLC enriched medium 
leads to an increase in symmetrical division. On the other hand, IR therapy did not change the 
CSLC division patterns. The possibility of therapeutic interventions affecting cell fate could alter 
the therapeutic effectiveness. For instance, if a targeted drug could shift the 
symmetrical:asymmetrical ratio towards asymmetrical division, classical therapeutic 
interventions could be more efficient. Possible limitations of our current work include the 
inability to assess the effects of the SC niche and the inability to test whether post-mitotic 
alteration of the daughter cells occurs (Beckmann, et al. 2007). For example, it is possible that a 
CSLC could differentiate post-mitosis; such a possibility could be only studied by lineage tracing 
experiments. Interestingly, research has shown that the NOTCH signaling pathway can post-
mitotically alter the developmental fate of cells (Betschinger and Knoblich 2004; Martinez Arias, 
et al. 2002). Overall, we believe that the manipulation of CSLC division from symmetrical to 
asymmetrical through therapeutics might be one approach to eradicating tumors. 
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4.4 DISTAL 11Q LOSS AND CHROMOSOMAL INSTABILITY IN OSCC CSLC  
Our group has demonstrated previously that distal 11q loss as marked by loss of the ATM gene 
plays a role in predicting radioresistance and a favorable response to combined therapy using IR 
and an ATR/CHEK1 pathway inhibitor. CSLC are a subset of cells that influence therapeutic 
resistance in cancers. Identifying CSLC-related DNA repair vulnerabilities might facilitate more 
effective therapeutic targeting of these cells. Understanding the role of ATM loss in CSLC will 
aid in highlighting the functional context of copy number alterations in CSLC. Like all cancer 
cells, CSLC are genetically heterogeneous and may acquire genetic changes that favor resistance 
to various therapeutic approaches (Bakhoum, et al. 2015; Gollin 2014; Lagasse 2008; Odoux, et 
al. 2008). 
Our results suggest that CSLC show genetic alterations identical to the genetic variations 
observed in non-CSLC (Figure 26; Table 7), suggesting a common ancestral origin and the 
possibility of a hierarchic model. The copy number variation observed within CSLC clones 
suggests that CSLC show different therapeutic resistance properties, a qualitative trait; and that 
the frequency of CSLCs, a quantitative trait in the tumor might not be the driving force behind 
CSLC therapeutic resistance (Figures 27, 28). Our current results suggest that CSLC frequency is 
not a consistent prognostic marker across OSCC (Table 2). Recently, in non-CSLC, 
chromosomal instability was shown to be an important factor driving radioresistance (Bakhoum, 
et al. 2015). Further assessment of the possible role of CIN in CSLC is warranted. 
Our results confirm the model presented by Lagasse suggesting that CSLC show dynamic 
rather than fixed therapeutic resistance (Lagasse 2008). The enhanced therapeutic resistance that 
occurs as a result of the complex interaction of stemness factors, driver mutations and copy 
number alterations may contribute to the unique evolutionary survival capacity of these cells 
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(Garcia, et al. 2000; Lagasse 2008). Understanding the mechanisms of CIN in oral CSLC will aid 
in devising approaches to understand which patients are more prone to therapeutic resistance 
(Bakhoum, et al. 2015). The genetic heterogeneity of CSLC will probably necessitate using 
multiple therapeutic approaches as well as re-assessing the genetic alterations in 
metastatic/recurrent tumors (Lagasse 2008). Although, CSLC and non-CSLC share important 
genetic alterations, curative rates in cancers are still not high and are sometimes inconsistent. For 
instance, in CML patients, where there are high remission rates due to targeted drugs against the 
BCR/ABL1 translocation, curative rates are intermediate and recurrence occurs due to 
development of bypass mutations in CSLC (Graham, et al. 2002; Lagasse 2008). 
4.5 SPHEROID ENRICHMENT IN OSCC 
Based on the current literature and the lack of a clear cut marker for CSLC, spheroid enrichment 
emerges as the most suitable approach to study CSLC (Pastrana, et al. 2011; Shrivastava, et al. 
2015). Growing CSLC in suspension or adherently attached on Matrigel™-coated plates were 
both utilized in our study. This enabled the versatility of studying and assessing more properties 
of CSLC. Morphologically, the spheroids were either spheroid (sphere-like) in shape or grape-
like in shape; both morphological types have been described previously in the literature (Hueng, 
et al. 2011; Lim, et al. 2011). In gliomas, spheroid/grape-like morphologies were associated with 
different genetic signatures and functional capacities; the typical spheroid morphology being 
associated with ESC origin and the grape-like morphology being associated predominantly with 
mesenchymal SC (MSC) origin. Such a possibility might exist across other tumors as well, and 
needs further investigation in our cell lines (Mao, et al. 2013). Adherent, enriched CSLC 
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characteristically grew as small tightly packed cells in rounded colonies similar to the holoclone 
morphology described by Locke et al. (Locke, et al. 2005). Locke et al. previously described that 
colonies in OSCC cell lines can be classified into: ‘holoclones’, ‘paraclones’ or ‘meroclones;’ 
holoclones are compact round colonies, paraclones are loose, irregular colonies, and meroclones 
have intermediate features. Holoclones are characteristically associated with CSLC (Locke, et al. 
2005). The in vitro colony classification and the higher frequency of CSLC were also identified 
in other tumors as well, such as lung SCC (Wang, et al. 2013) and pancreatic cancer (Tan, et al. 
2011). 
Spheroid enrichment as an approach for studying CSLC has advantages and 
disadvantages. Advantages include that the approach is more affordable and more versatile when 
compared to FACS. Second, the approach has been standardized (Pastrana, et al. 2011; Vinci, et 
al. 2013). Disadvantages include that spheroids do not enrich exclusively for CSLC; second, not 
all spheroids arise from SCs, but sometimes from transient progenitor cells as well; third, 
spheroids might not arise from quiescent SCs; fourth, spheroids might aggregate, leading to 
difficulties in assessing clonality (Friedrich, et al. 2009; Pastrana, et al. 2011; Perego, et al. 
2011). Improvements and modifications to the spheroid enrichment procedure have potentially 
eliminated some of the disadvantages. For instance, assessing clonality is critical in assessing 
self-renewal and/or therapeutic response; this issue has been overcome by ensuring a proper 
clonal density of 0.2 to 20 cells per µL which can be achieved by using limiting dilution. 
Research has shown that spheroid diameter ranges from 40–150 µm and that bigger spheroids 
tend to originate from SC and smaller spheroids from progenitor cells (Pastrana, et al. 2011). In 
addition, the use of adherent systems with CSLC-enriched medium, a modification to the non-
adherent system, is rapidly gaining ground as it ensures full exposure of adherent CSLCs to the 
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enriched medium thereby inhibiting CSLC differentiation and increasing CSLC propagation 
(Woolard and Fine 2009). As our understanding of CSLC biology and the CSLC niche 
progresses, bioengineering approaches will enable researchers to create an in vitro substrate 
similar to the in vivo extracellular matrix. Such models will yield information with high 
translational value (Vunjak-Novakovic and Scadden 2011). 
4.6 CSLC RADIORESISTANCE PATTERNS IN OSCC 
CSLCs have been found to contribute to therapeutic resistance, recurrence and metastasis. If the 
proportion of CSLCs in tumors could be targeted and reduced, then the mortality rates of patients 
may improve. Our results using a variety of approaches showed that enriched CSLCs are 
resistant to IR through different approaches (Figure 36-46). To simulate the clinical setting, we 
administered IR regimens (2.5 Gy IR EOD*3) and (2.5 Gy IR EOD*6), to CSLC-enriched 
cultures and assessed the colony forming capacity of both regimens. Spheroid-enriched CSLC 
showed persistent radioresistance across both regimens (Figure 45).  
To study the role of distal 11q loss in CSLC radioresistance we used a number of 
experimental approaches. Both spheroid survival and cell viability assays showed similar 
radioresistance trends based on distal 11q (Figure 36-40). However, the analysis of spheroid size 
and ELDA in response to IR did not differ as a function of distal 11q loss (Figure 41-44; Table 
9), suggesting a possible complex role of distal 11q loss in OSCC. Overall, our CSLC 
therapeutic radioresistance trends seem to coincide with the patterns observed by Chen et al. in 
OSCC (Chen, et al. 2012). Chen et al. showed that different IR regimens (up to 10 Gy) did not 
lead to a statistically significant reduction in CSLC survival; while on the other hand, parental 
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cancer cells showed an IR dose-dependent reduction in survival (Chen, et al. 2012)  Unlike the 
results shown by Lagadec et al. and Ghisolfi et al. (Ghisolfi, et al. 2012; Lagadec, et al. 2010), 
the IR regimens did not enrich the cell lines for CSLC. Our results suggest that IR may not be a 
suitable CSLC enrichment tool across different tumors. This could possibly be due to the 
heterogeneity of solid tumors and the different genetic signatures of each tumor type.   
One of the limitations of the spheroid survival assay is that spheroids are motile and they 
might merge, leading to inaccuracies in the estimation of the number of colonies (Singec, et al. 
2006). To overcome this limitation we repeated the experiments three times. Furthermore, 
appropriately low clonal density was used in these experiments (Pastrana, et al. 2011). In 
addition, other approaches, such as viability assays, proliferation assays, ELDA and migration 
assays were done to confirm our findings. Unlike the early days of CSLC culture (Singec, et al. 
2006), many labs are currently using standardized spheroid culturing approaches, decreasing 
experimental variability based on the approach. In addition, the spheroid growth and extreme 
limiting dilution assays using lower cell density in 96-well plates allowed us to assess the 
therapeutic effect more thoroughly (Singec, et al. 2006). A real problem that we faced in the 
project was isolating CSLC from spheroids for further assessment of CSLC properties of 
proliferation, differentiation, viability and segregation defects. We tried a number of approaches 
to dissociate spheroids into single cell suspensions, but the net yield was usually low (Woolard 
and Fine 2009). We decided to isolate the CSLC based on their Matrigel™ migration, in addition 
to a secondary enrichment process on another Matrigel™ substrate. This dual enrichment 
approach yielded a sufficient number of CSLC for further experimentation. The approach also 
incorporated the important advantages of CSLC enrichment observed in adherent monolayers; 
most importantly, the long-term serial passaging potential, the ease of further experimentation 
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and the possibility of establishing stable CSLC cell lines (Sun, et al. 2008; Woolard and Fine 
2009). Two important limitations of the approach include the problem that not all enriched 
spheroids migrate on Matrigel™ plates and the time factor, as this approach takes double the 
time of any other one step adherent or non-adherent culturing method.   
The radioresistance of CSLC might be explained by the different gene expression pattern 
of CSLC when compared to parental cell lines as shown previously by Wilson et al. (Wilson, et 
al. 2013). The results of our assessment of gamma-H2AX foci post-IR in CSLC compared to 
parental tumors (Parikh, et al. 2007) showed that CSLC expressed more foci, which indicates 
that these cells might be detecting DNA damage more efficiently than non-CSLC (Figure 47). 
Assessing KU70 and pCHEK1 foci post-IR also showed statistically significant changes in 
CSLC, confirming the role of the DDR in CSLC as well as non-CSLC (Sankunny, et al. 2014).  
Traditional culture approaches for the evaluation of tumor cell initiation, migration and 
invasion in vitro generally employ two-dimensional (2D) cultures that do not represent the 
dynamics of how tumor colonies grow and invade the extracellular matrix proteins. Three-
dimensional colony formation can more accurately reflect the complexity of cell-cell interaction 
and cell-environment interaction to a large extent (Vinci, et al. 2013). The spheroid migration 
model (Figure 51) depicts the critical mobilization of the tumor into the surrounding matrix, a 
process called ‘infiltration’ and the establishment of new colonies in secondary organs, a process 
critical in carcinogenesis and referred to as ‘metastasis.’ This critical process is usually 
associated with the poor prognosis that is reflected in the advanced tumor staging of these 
patients. Our results show that migratory CSLC were radioresistant, and that the overall trend in 
response to IR is similar to spheroid survival, spheroid growth and cell viability assays (Figures 
36-46).  
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Figure 51. Spheroid migration zone assay for short-term therapeutic assessment 
 
A. The spheroid enriched for CSLC attaches to the extracellular matrix coating, such as 
Matrigel™. 
B. The attached CSLC in the spheroid then migrates on the extracellular matrix.  
C. The migration area can be assessed and normalized to the original spheroid area.   
4.7 COMBINED IR AND ATR/CHEK1 PATHWAY INHIBITION OF CSLC IN 
OSCC 
Conventional IR and chemotherapy treatment seem incapable of preventing tumor recurrence 
and/or metastases in OSCC, possibly due to therapeutic resistance of CSLC. The radioresistance 
of CSLC that we and others have observed makes exploration of novel strategies to inhibit 
CSLCs a necessity (Bao, et al. 2006). The work of Bao et al. in glioma CSLC showed that DDR 
inhibitors might hold the promise of targeting CD133-positive CSLC when compared to CD133-
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negative CSLC (Bao, et al. 2006). The effectiveness of new DDR-targeted agents, which have 
been effective experimentally in various cancers need to be studied thoroughly in CSLC as 
potential targeted therapies.  
The spheroid (3D) survival assay that we used in our study has a number of advantages 
that makes the assay system more robust and reliable than conventional monolayer (2D) culture. 
These advantages include: the limitation in drug penetration, contact-dependent multidrug 
resistance, and hypoxia (Friedrich, et al. 2009). Our results show that the combination of 
IR/CHEK1 may not always inhibit CSLC. An effective CHEK1 dose of 540 nM in parental cell 
lines did not affect the colony forming capacity or survival of CSLC; a dose-response curve 
showed that only a 100-fold higher dose of the drug could inhibit CSLC. Our results concur with 
those of Francipane and Lagasse, who found that of six different mTOR targeting compounds, 
only one compound at a high concentration produced a statistically significant reduction in 
survival (Francipane and Lagasse 2013). In ESC, at least a 10-fold higher dose of ATM inhibitor 
was necessary to inhibit ATM function when compared to somatic cells (Momcilovic, et al. 
2010). These results suggest that the ESC genetic signature might be playing a role in CSLC as 
shown previously by others (Mao, et al. 2013). Further, assessment of the genetic signature of 
the CSLC enriched-spheroids and parental OSCC is warranted to investigate possible therapeutic 
targets specific to OSCC. 
The high CHEK1 inhibitor dose might suggest that CSLC have higher drug efflux 
capacity as previously shown by others (Liu, et al. 2012; Monzani, et al. 2007). We observed no 
response based on ‘Distal 11q loss’ in CSLC as previously shown in non-CSLC, this observation  
suggests that CSLC does not respond in the same ways as cancer cells and that the stemness 
property overrides many important factors that drive radiosensitivity in cancer cells.  
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Overall, our results suggest that distal 11q loss (ATM loss) might be a useful marker in 
conjunction with other markers in assessing radioresistance of CSLC. Unlike parental cell lines, 
CSLC seem to be more robust and were radioresistant despite a two week regimen; suggesting a 
more complex DDR in CSLC when compared to non-CSLC. Our study had some limitations. 
Our data only provided in vitro evidence of the radiosensitizing effect of CHEK1 knockdown on 
the enriched OSCC CSLC, lacking in vivo evidence; future in vivo studies are important to 
confirm our findings. However, the present study suggests for the first time, that CHEK1 
knockdown radiosensitizes and limits the local invasion of OSCC CSLCs. Future directions of 
our work include further assessing possible cell surface CSLC markers, in vivo studies, 
combination DDR inhibitors and functional studies to understand the DDR in CSLC. Combining 
other DDR inhibitors, such as PARP or WEE1 inhibitors to a CHEK1 inhibitor may be important 
to achieve tolerable therapeutic concentrations of these drugs. Such a step would be critical 
before progression to clinical trials can be achieved. 
4.8 CONCLUSION 
Recent developments in CSLC research have added further evidence to support the role of CSLC 
in therapeutic resistance. The characterization of CSLC in OSCC will greatly advance our 
understanding of these tumors. In the current study, we demonstrate that compared to parental 
cancer cells, spheroid-enriched CSLCs possess features of stemness and display enhanced 
radioresistance, asymmetrical cell division, clonogenicity, tumorigenicity, and a more robust 
DDR-sensing machinery. Definitive CSLC markers for OSCC have yet to be characterized, 
although several studies have proposed different markers. Our results suggest that the use of dual 
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markers identification is important for better identification of CSLC in OSCC. CD133/SOX2 
dual staining was the most promising combination in our study. SOX2 plays an important role in 
regulating stemness in both CSLC and normal SC (Tian, et al. 2012). Our finding that this 
marker can be used to assess the division patterns of CSLC, adds evidence that SOX2 is useful in 
the identification of CSLC. In addition, the expression of SOX2 may be a potential prognostic 
biomarker in OSCC (Li, et al. 2014). Limitations of the current study include the reliance on the 
in vitro model which needs to be confirmed using an in vivo model, and the exclusion of 
ALDHA1 from our CSLC marker panel analysis. We assessed the possible prognostic 
significance of CSLC markers (CD44, CD133/1, SOX2 and BMI1) in a panel of OSCC cell lines 
that were previously studied in our lab (White, et al. 2007). We did not observe prognostic 
significance based on these markers; this might be due the small sample size, the use of low 
passage cell lines rather than primary tumors, possibly confirming the observations that CSLC 
markers may not be suitable independent prognostic markers, as observed by others (Table 7). 
One of the main objectives of our study was to assess the radioresistance patterns of 
spheroid-enriched CSLC in comparison to parental cancer cells (Parikh, et al. 2007; Sankunny, et 
al. 2014). There was a statistically significant difference between the parental cells and CSLC 
based on colony forming capacity tests. We observed statistically significant differences in 
radioresistance by spheroid survival and cell viability based on distal 11q loss. On the other hand 
we observed no statistically significant differences in radioresistance based on distal 11q loss 
using ELDA and spheroid growth assays. The response of CSLC to combined IR and CHEK1 
inhibitor was totally different when compared to parental cancer cells. A 100-fold higher CHEK1 
inhibitor dose was required to inhibit CSLC colony forming capacity, cell survival, and colony 
growth. As discussed earlier, we believe that the stemness of CSLC supersedes possible cancer 
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cell biomarkers. This observation needs to be confirmed in a larger study, assessing other OSCC 
biomarkers in CSLC and assessing the genetic signature of OSCC CSLC in comparison to 
parental cancer cells. Future directions of our work include assessing the value of flow cytometry 
sorted CSLC to confirm the radioresistance of these cells and to assess their response to IR and 
CHEK1 combination; in vivo studies to confirm the response of CSLC to IR and CHEK1 
combination; functional studies to understand the DDR in CSLC compared to parental cancer 
cells. Combining other DDR inhibitors, such as PARP inhibitors with CHEK1 inhibitors could 
possibly be synergistic and effective in achieving tolerable therapeutic drug concentrations of 
these drugs. Such a step would be necessary before progress into clinical trials can be achieved. 
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APPENDIX A: CHEKI SMALL MOLECULE INHIBITOR 
PF-0077736, a potent, specific CHEK1 small molecule inhibitor (SMI) was a purchased from 
Selleck Chemicals, Houston, TX, USA. 
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APPENDIX B: LIST OF ANTIBODIES USED FOR IF 
Antibody Type Company Catalog 
No. 
Dilution 
CD44 Mouse Monoclonal BD 550392 1:100 
CD133 Rabbit Abcam Ab19898 1:200 
CD133/1(AC133) Mouse IgG1 
Monoclonal 
Miltenyi Biotec 130-090-
422 
1:10 
CD133/1 (AC133)-
VioBright FITC 
Mouse IgG1 
Monoclonal 
Miltenyi Biotec 130-105-
226 
1:10 
CD133/1 (AC133)-PE Mouse IgG1 
Monoclonal 
Miltenyi Biotec 130-098-
826 
1:10 
BMI1 Rabbit Polyclonal Imgenex IMG-
6362A 
1:400 
BMI1 Mouse Abcam Ab14389 1:400 
SOX2 Rabbit Polyclonal Imgenex IMG-
6507A 
1:400 
Nestin Rabbit Polyclonal Imgenex IMG-
6492A 
1:400 
Anti-gamma H2A.X 
(phospho S139)  
Rabbit Abcam ab11174 1:500 
Phospho-histone H3 Mouse Cell Signaling 9706S 1:100 
Alpha-beta tubulin Rabbit Polyclonal Cell Signaling 2148S 1:50 
Gamma tubulin Rabbit Sigma T3559 1:1000 
KU70 Mouse BD 611892 1:100 
pCHEK1 Rabbit Cell Signaling 2348S 1:100 
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APPENDIX C: LIST OF ANTIBODIES USED FOR FLOW CYTOMETRY 
Antibody Type Company Catalog 
No. 
Dilution 
CD44 Mouse monoclonal 
FITC 
BD 555478 1:100 
CD133/1 (AC133)-PE Mouse IgG1 
Monoclonal 
Miltenyi Biotec 130-098-
826 
1:10 
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APPENDIX D: ABBREVIATIONS 
AT - Ataxia telangiectasia 
ATM – Ataxia telangiectasia mutated  
ATR - Ataxia telangiectasia and Rad3-related  
ATRIP - ATR interacting protein   
BER - Base excision repair  
BFB - breakage-fusion-bridge  
CIN – Chromosomal instability 
CSC - Cancer stem cell  
CSD - Chromosomal segregation defects 
CSLC – Cancer stem-like cell   
DDR - DNA damage response  
DFS – Disease-free survival 
DSB - Double-strand break  
EGFR - Epidermal growth factor receptor 
ELDA – Extreme limiting dilution analysis  
EMT – Epithelial-mesenchymal transition  
EOD – Every other day 
ESC - Embryonic stem cells 
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FACS – Flow cytometry cell sorting 
FGF - Fibroblast growth factor 
HNSCC – Head and neck squamous cell carcinoma 
HR - Homologous recombination  
IF – Immunofluorescence 
IHC – Immunohistochemistry 
IR – Ionizing radiation 
MC - Mitotic catastrophe 
MMR - Mismatch repair  
MRN - MRE11A-RAD50-NBN  
MSC - Mesenchymal stem cell 
MTOR - Mammalian target of rapamycin 
NER - Nucleotide excision repair  
NHEJ - Non-homologous end joining 
NSCLC – Non-small cell lung carcinoma  
OS – Overall survival 
OSCC – Oral squamous cell carcinoma 
PARP - Poly (ADP-ribose) polymerase 
PBS - Phosphate buffered saline  
PRKDC - Protein kinase, DNA-activated, catalytic polypeptide 
RPA - Replication protein A  
RT - Room temperature 
SC - Stem cell 
 146 
SCC - Squamous cell carcinoma 
SFE - Spheroid forming efficiency 
ShRNA - Short hairpin RNA 
siRNA - Small interfering RNA 
SMG1 - Suppressor of morphogenesis in genitalia-1 
SMI - Small molecule inhibitor 
SOX2 - Sex-determining region Y [SRY]-box  
SP – Side population 
SSB – Single-strand break  
TRRAP - Transformation/transcription domain-associated protein 
UT - Untreated 
UV - Ultraviolet light 
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